Functional characterization of anti-idiotypic antibody expanded chimeric antigen receptor (CAR) expressing re-directed T cells by Jakka, Gopinadh
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Functional characterization of anti-idiotypic antibody expanded chimeric
antigen receptor (CAR) expressing re-directed T cells
Jakka, Gopinadh
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-164319
Dissertation
Published Version
Originally published at:
Jakka, Gopinadh. Functional characterization of anti-idiotypic antibody expanded chimeric antigen re-
ceptor (CAR) expressing re-directed T cells. 2012, University of Zurich, Faculty of Science.
 Functional Characterization of Anti-idiotypic Antibody 
Expanded Chimeric Antigen Receptor (CAR) Expressing 
Re-directed T Cells 
 
Dissertation 
 
zur 
 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr.sc.nat.) 
 
vorgelegt der 
 
Mathematisch-naturwissenschaftlichen Fakultät 
 
der 
 
Universität Zürich 
 
von 
 
Gopinadh Jakka 
 
aus Indien 
 
 
Promotionskommitee 
 
Prof. Dr. Christoph Renner (Vorsitz, Leitung der Dissertation) 
Prof. Dr. Anne Müller 
Prof.Dr. Martin Pruschy 
Prof. Dr. Maries van den Broek 
 
 
Zürich, 2013 
 
Page I 
 
This work has been conducted under the supervision of  
Prof. Dr. Christoph Renner 
Department of Oncology 
University Hospital Zurich 
Rämistr. 100, CH-8091 Zürich 
Switzerland 
Page II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E r k l ä r u n g :  
 
Ich versichere, dass ich die Dissertation selbstständig gefertigt, alle benutzten Quellen und 
Hilfsmittel angegeben und Zitate im Text kenntlich gemacht habe. Ich versichere ferner, dass 
ich die Arbeit weder ganz noch teilweise für eine Prüfung an einer Hochschule eingereicht 
habe. 
 
 
Zürich, 19.12.2012 
 
 
 
 
Page III 
Abstract 
 
Cancer immunotherapy is aimed to activate the immune system to fight cancer. Tumor 
associated antigens (mostly self-antigens) recognized by cellular or humoral effectors of the 
immune system are potential targets for an antigen specific cancer therapy. Tumor specific 
CD8+ cytotoxic T cells play a critical role in the recognition and elimination of tumor cells. 
Transfusion of ex vivo expanded tumor specific T cells in tumor bearing hosts is known as 
adoptive T cell-therapy. It is widely accepted that cancer cells not only escape from immune 
recognition but also suppress anti-tumor immune response. Therefore, not all tumors induce 
tumor specific T cells. To overcome this problem, recombinant T cell-receptors can be 
expressed in peripheral blood T cells conferring a new specificity. T cells expressing chimeric 
antigen receptors composed of either antibody-derived Fab or single-chain variable fragment 
(scFv) as their extracellular recognition elements joined to lymphocyte triggering molecules (e.g. 
TCR-zeta chain, CD28) are known as re-directed T cells. 
The Cancer-Testis (CT) antigen NY-ESO-1 is expressed in a variety of cancers but not in 
normal adult tissue except for the reproductive tract. NY-ESO-1 is immunogenic, spontaneous 
humoral and CD8+ T cell responses can be detected in patients with advanced NY-ESO-1 
expressing tumors. Due to its tumor-specific expression, it has been targeted by various 
immuno-therapeutical strategies. Effective cancer immunotherapy depends on the presence of 
a sufficiently large number of CD8+ lymphocytes with anti-tumor specificity and appropriate 
homing and effector functions, enabling recognition and destruction of cancer cells. Transfer of 
ex vivo generated CD8+ T cells with chimeric receptors specific for cancer antigens is a 
promising approach. 
In the present study, we expressed chimeric antigen receptors on human CD8+ T cells via 
retroviral mediated gene transfer. These receptors are composed of single chain variable 
fragments of various affinities derived from an antibody recognizing the NY-ESO-1157-165 peptide 
presented in the HLA-A2 complex (TCR like antibody) fused to an intracellular signalling domain 
of CD28 and CD3 zeta. These re-directed CD8+ T cells show differences in cytotoxicity and 
IFN-gamma production in response to NY-ESO-1 expressing tumor cells with respect to their 
affinity. Treatment with the DNA demethylating agent 5-aza-2-deoxycytidine increases or 
induces the expression of NY-ESO-1 in various tumor cell lines thus enabling or enhancing the 
effective killing by NY-ESO-1 specific re-directed T cells. We also showed that anti-idiotypic Fab 
fragments specifically bound to anti-NY-ESO-1157–165 CAR and activation of anti- NY-ESO-1 
CAR re-directed T cells with anti-idiotypic antibodies was comparable to stimulation with cells 
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presenting large amounts of HLA-A*0201/NY-ESO-1157–165 complexes with respect to 
functionality in vitro and in vivo . Stimulation with anti-idiotypic antibodies resulted in 300 fold 
expansion of re-directed T cells. 
Based on our results, we propose the use of high affinity CAR re-directed T cells for adoptive T 
cell therapy and anti-idiotypic antibodies, which can easily be adapted to GMP regulations, to 
expand and activate re-directed T cells for therapeutic use. 
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Zusammenfassung 
 
Es ist bekannt, dass das Immunsystem in der Lage ist, Tumorzellen zu erkennen und 
abzutöten. Tumor-assoziierte Antigene, die durch die zelluläre oder humorale Immunantwort 
erkannt werden, sind hierbei potentielle Zielstrukturen für eine antigen-spezifische 
Immunantwort. Tumor-spezifische CD8+ zytotoxische T-Zellen spielen eine wichtige Rolle bei 
der Erkennung und Beseitigung von Tumorzellen. Während der Tumorentstehung können die 
Tumorzellen aber zum einen der Immunerkennung entkommen, zum anderen auch die 
Immunantwort gegen den Tumor aktiv unterdrücken. Daher konnten nicht bei allen Patienten 
tumor-spezifische T-Zellen nachgewiesen werden. Um dieses Problem zu überwinden, können 
rekombinante chimäre T-Zell-Rezeptoren in peripheren Blut-T-Zellen exprimiert werden, die 
dadurch eine neue Spezifität erhalten, die gegen die Tumorzellen gerichtet ist. Zur 
Antigenerkennung werden chimäre Antigen-Rezeptoren (CAR) benutzt, die aus Antikörper-
abgeleiteten Fab-Fragmenten oder single-chain variablen Fragmenten (scFv) bestehen. Diese 
CARs sind zur T-Zell-Aktivierung mit Signaldomänen (z.B. TCR--Kette, CD28) fusioniert. Diese 
CAR tragenden T-Zellen werden als „re-directed“ T-Zellen bezeichnet. Die Transfusion von ex 
vivo expandierten tumor-spezifischen re-directed T-Zellen in Patienten ist als „Adoptive T-Zell-
Therapie“ bekannt und bereits in der klinischen Testung. 
Das CT-Antigen NY-ESO-1 wird in einer Vielzahl von Krebsarten exprimiert, aber nicht in 
normalem adulten Gewebe mit Ausnahme des Keimzellgewebes. Bei einem Teil der Patienten 
mit fortgeschrittenen NY-ESO-1 exprimierenden Tumoren konnte eine spontane humorale und 
CD8+ T-Zell Reaktion nachgewiesen werden. Aufgrund seiner tumor-spezifischen Expression 
dient NY-ESO-1 als Ziel für verschiedene immuntherapeutische Strategien. Eine wirksame 
Immuntherapie hängt von der Anwesenheit einer ausreichend großer Anzahl tumor-spezifischer 
und funktionaler CD8+ T-Zellen ab. Um dieses Ziel zu erreichen, ist der adoptive Transfer von 
ex vivo generierten und expandierten CAR tragenden CD8+ T-Zellen ein vielversprechender 
Ansatz. 
In der vorliegenden Studie haben wir CARs in humanen CD8+ T-Zellen mittels retroviralen 
Gentransfer exprimiert. Diese Rezeptoren basieren auf einem scFv, der spezifisch gegen den 
HLA-A*0201/NY-ESO-1157-165-Komplex (TCR like antibody) gerichtet war. Hierbei wurden 
scFv mit verschiedener Affinität getestet. Der scFv wurde fusioniert mit den intrazellulären 
CD28- und CD3 Signaldomänen. Diese re-directed CD8+ T-Zellen zeigten Unterschiede in 
ihrer Zytotoxizität und Interferon-gamma-Produktion in Abhängigkeit von Antigendichte auf den 
Tumorzellen und der Affinität des CAR. Zur Steigerung der Antigendichte auf den Zielzellen 
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wurde die DNA-demethylierende Substanz 5-Aza-2-desoxycytidin getestet. Diese verstärkte 
oder induzierte die Expression von NY-ESO-1 in verschiedenen Tumorzelllinien, wodurch die 
NY-ESO-1 spezifischen re-directed T-Zellen eine verbesserte Wirkung zeigten. 
Darüber hinaus konnte gezeigt werden, dass anti-idiotypische Fab-Fragmente spezifisch am 
anti-NY-ESO-1 CAR banden. Basierend auf dieser Beobachtung wurde das 
Aktivierungsverhalten der anti-NY-ESO-1 CAR tragenden re-directed T-Zellen analysiert, 
nachdem sie mit Zellen oder dem Anti-Idiotypen stimuliert wurden. Hierbei konnte beobachtet 
werden, dass die Stimulation mit dem anti-idiotypischen Antikörper vergleichbar war mit Zell-
basierter Stimulation, die den HLA-A*0201/NY-ESO-1157-165 Komplex in hoher Dichte 
exprimierten. Die Stimulierung mit anti-idiotypischen Antikörpern führte zu einer 300-fachen 
Expansion der re-directed T-Zellen und war somit signifikant grösser als bei der Zell-basierten 
Expansion. Es gab nach den beiden unterschiedlichen Stimulationen keinen Unterschied 
zwischen der Funktionalität in vitro und in vivo. Basierend auf unseren Ergebnissen, schlagen 
wir die Verwendung von CAR re-directed T-Zellen für die adoptive T-Zell-Therapie vor, die 
durch die Verwendung von anti-idiotypischen Antikörpern expandiert wurden. Da hierbei das 
Expansionssystem Zell-frei ist, kann dieser Prozess einfacher GMP-konform durchgeführt 
werden. Die Expansion und Aktivierung von re-directed T-Zellen soll später für therapeutische 
Zwecke genutzt werden. 
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1 Introduction 
Hundred years ago, it was postulated that the immune system effectively protects the host from 
various infections and might also destroy tumor cells. Today it has been widely accepted that 
the immune system is protecting the host from tumor formation. However, the immunological 
processes leading to protection are a complex interplay of the tumor tissue and the immune 
system. 
1.1 Immunosurveillance 
A fundamental principle of immunosurveillance is the recognition of tumor specific antigens 
expressed on tumor cells that are different from their parental cells. The hypothesis of 
immunosurveillance came from the basic experiments performed by Burnet and Thomas 
(Burnet 1957); they proposed that adoptive immunity was mainly involved in suppressing tumor 
growth (Stutman 1974; Stutman 1975). The immunosurveillance hypothesis was supported by 
experiments with immunodeficient mice that showed more susceptibility to induced tumors than 
immunocompetent mice (Dighe, Richards et al. 1994; Kaplan, Shankaran et al. 1998). 
Experiments in 2001 demonstrated that the immune system not only controlled the tumor 
growth but also could support tumor progression. In those experiments, tumor formation was 
rejected in wild type mice when transplanted tumor cells derived from immunodeficient mice, 
whereas progressive tumor growth was observed when wild type mice derived tumor cells were 
used. These results strongly supports that the immune system not only protects but also edits 
the immunogenicity of the tumor cells (Shankaran, Ikeda et al. 2001; Cheever, Allison et al. 
2009). 
1.2 Immunoediting 
Cancer immunoediting is a complex process, composed of three distinct phases termed 
elimination, equilibrium and escape (Vesely, Kershaw et al. 2011). During the elimination phase 
both innate and adoptive immune systems work together to detect and eliminate tumors before 
they become clinically apparent (Girardi, Oppenheim et al. 2001; Dunn, Old et al. 2004; Guerra, 
Tan et al. 2008). Although activation of the innate immune system controls the tumor growth, 
effective immunosurveillance depends on expansion of antigen specific CD4+ and CD8+ T cells 
(Matsui, Ahlers et al. 1999; Guerra, Tan et al. 2008; Vesely, Kershaw et al. 2011). In the case of 
ineffective elimination of the tumor cells an equilibrium state between cancer cells and immune 
cells will be reached. During this phase the immune system controls measurable tumor 
outgrowth, however tumor cells are present. The equilibrium phase is the longest phase in 
cancer immunoediting (Aguirre-Ghiso 2007). During the escape phase, tumor cells acquire the 
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ability to escape from immune recognition and grow to viable and clinical relevant tumors 
(Dunn, Bruce et al. 2002; Khong and Restifo 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1:  Three phases of cancer immunoediting (Vesely, Kershaw et al. 2011) 
1.3 Tumor antigens 
With the advance of technology, several different tumor associated antigens (TAAs) and tumor 
specific antigens have been identified (van der Bruggen, Traversari et al. 1991; Traversari, van 
der Bruggen et al. 1992; Sahin, Tureci et al. 1995). Pfreundschuh and his colleagues have 
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identified a panel of different antigens  with the help of SEREX (Serological analysis of antigen 
by recombinant expression cloning). SEREX allows the identification of tumor antigens that elicit 
humoral immune response in cancer patient. Since then, several different tumor antigens have 
been identified with the help of SEREX (Sahin, Tureci et al. 1995). Based on their expression 
tumor antigens are classified into different categories as shown in below table (Chen, Scanlan 
et al. 1997; Scanlan, Gure et al. 2002).  
Antigen group Antigen name 
Cancer-testis (CT) antigens 
 
Differentiation antigens 
Oncofoetal antigens 
Overexpressed antigens 
Mutational antigen 
Retroviral antigens  
Splice variant antigens 
MAGE-1,MAGE-2, MAGE-12, BAGE, NY-ESO-1 
and CML66 
Tyrosinase, TRP-1, TRP-2, gp100 and MART-1 
CEA, α-fetoprotein and 5T4 
WT-1, MUC-1, proteinase 3 and G250 
P53  
HERV-K10 
NY-CO-30 
 
1.4 Cancer-testis antigen NY-ESO-1 
NY-ESO-1 is one of the cancer testis (CT) antigens that were first discovered by SEREX (Chen, 
Scanlan et al. 1997). It was identified in a serum from a patient with squamous cell carcinoma of 
the esophagus (Chen, Gure et al. 1998). Expression of the NY-ESO-1 protein is strictly 
restricted to tumor cells as well as immune-privileged regions (germ cells and placenta) (Lethe, 
Lucas et al. 1998). The molecular weight of the NY-ESO-1 protein is 18KD and contains 180 
amino acids. The biological function of the NY-ESO-1 protein is not completely known. 
Several studies showed that NY-ESO-1 induces a spontaneous cellular and humoral immune 
response in patients with metastatic melanoma and other tumor types (Fossa, Berner et al. 
2004; Gjerstorff, Kock et al. 2007). Furthermore, it has been demonstrated that NY-ESO-1 
elicits both CD8 and CD4 T cell responses in patients with different tumor types, and large 
number of CD4 and CD8 T cell epitope has been identified (Jager, Chen et al. 1998; Tsuji, 
Hamada et al. 2008). The NY-ESO-1157-165 peptide is one of the immunogenic NY-ESO-1 
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peptide and induces spontaneous T cell response in patients with different cancers (Yuan, 
Adamow et al. 2011). In peptide vaccination trails with the NY-ESO-1157-165 peptide showed 
strong CTL response and lysed the tumor cells expressing NY-ESO-1157-165 peptide (Tsuji, 
Hamada et al. 2008). 
1.5 T cell responses 
Specificity of each T lymphocyte is determined by the expression of a unique T-cell receptor 
(TCR) on the cell surface. Matured naive T cells migrate to secondary lymphoid organs through 
blood and lymphatic system where they will be activated by dendritic cells (DCs). Antigen 
presenting cells (mainly DCs) present antigenic peptides to naïve T cells from infectious agents 
or self-antigens in the context of MHC molecules. Interaction between an antigen-specific TCR 
of naïve T cells and a peptide/MHC molecule triggers series of intracellular signaling events 
resulting in T cell activation and maturation. An antigen specific activated T cell migrates 
through tissues to the site of infection or antigen presence and mediates cell-mediate effector 
function (Chtanova, Han et al. 2009). CD8+ T cells are mainly involved in target cell lysis, 
whereas helper CD4+ T cells produce important cytokines to orchestrate the adaptive and 
innate immune response. CD8+ T cells recognize peptides that are presented in the context of 
the MHC class I molecule, whereas helper CD4+ T cells recognize peptide in the context of 
MHC class II. Antigen specific activated CD8+ T cells release cytokines like IFNγ and TNFα, 
which enhance the expression of tumor antigens by increasing the expression of MHC class I 
and class II molecules on tumor cell surface. (Hung, Hayashi et al. 1998; Tosolini, Kirilovsky et 
al. 2011).(Fefer 1969). CD4 T cells also play critical role in autoimmunity, allergic responses 
and tumor immunity. During antigen specific activation naïve CD4 T cells may differentiate in to 
one of the different T helper (Th) cells, including Th1, Th2, Th17 and Tregs in the presence of 
particular cytokine. Depending on cytokine production, Mosmann and Coffman designated Th1 
and Th2 responses (Mosmann, Cherwinski et al. 1986). Th1 cells mainly produce IFNγ and tend 
to produce IL-2 and TNFα, whereas Th2 fail to produce IFNγ and mainly produce IL-4. In 1995, 
a third subset of CD4+ T cells was identified with suppressor activity. These cells were termed 
regulatory T cells or Tregs (Sakaguchi, Sakaguchi et al. 1995). In 2003, fourth effector CD4 T 
cell population was identified and designated as Th17 cells, known to produce IL-17A,IL-17F 
and IL-22 cytokines, which are not produced by Th1 and Th2 cells(Park, Li et al. 2005).   
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Figure 1-2: Schematic representation of MHC class I (left) and MHC class II (right) antigen presentation 
pathways (Janeway CA, Travers P, Walport M, Shlomchik M. Immunobiology. ISBN: 0-4430-7098-9). 
1.6 Spontaneous T cell response to cancers 
Several studies demonstrate that both CD4+ and CD8+ T cell immune responses against tumor 
associated antigens (TAAs) are spontaneously induced in the phase of cancer 
immunosurveillance in humans (Vesely, Kershaw et al. 2011). Strong evidence suggests that 
spontaneous elimination of melanoma lesions mainly depends on the expansion of antigen 
specific T cells. Several clinical studies showed that antigen specific spontaneous CD4+ and 
CD8+ T cell response target tumor associated antigens including NY-ESO-1 and MART-
1/Melan-A in cancer patients, whereas spontaneous T cell response against other TAAs are 
rare (Weide, Zelba et al. 2012). Spontaneous tumor regression was observed by lymphocyte 
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infiltration in various tumor types. Many studies demonstrated that presence of tumor-infiltrating 
lymphocytes (TILs) in melanoma. Patients with high levels of CD8+ T cells infiltrating the tumor 
tissues showed prolonged survival when compared to patients with low TIL numbers (Gooden, 
de Bock et al. 2011). The presence of intra-tumoral CD8+ T cells is associated with superior 
survival also in squamous cell and adenocarcinomas (Schumacher, Haensch et al. 2001).  
1.7 Tumor infiltrating T cells 
During the process of the adaptive immune response, T cells migrate and accumulate at the 
tumor site upon antigen encounter and are called TILs. T cells migrate through tissues and 
recognize infected cells or cells expressing altered protein molecules in the form of peptides 
presented on the cell surface through the major histocompatibility complex (MHC)(Deguine, 
Breart et al. 2010). The main effector function of T cells during the adaptive immune response 
includes target cell lysis and production of cytokines. Requirements for optimal activation and 
proliferation of T cells are the recognition of the cognate peptide through the TCR engagement 
and signaling via co-stimulatory receptors binding to their ligands expressing on antigen 
presenting cells or tumor cell surface. However, chronic antigen contact leads to exhaustion due 
to the chronic activation or activity T cells (Moskophidis, Lechner et al. 1993).  
Furthermore, TILs encounter immunosuppressive mechanisms at the tumor site (Restifo, 
Marincola et al. 1996; Schreiber, Old et al. 2011). Advanced technologies are available allowing 
the culturing and manipulating of T cells for improving their therapeutic efficacy. TILs can be 
isolated from tumor tissues and in vitro culturing could restore their activity. Adoptive transfer of 
fully functional in vitro expanded TILs has shown promising clinical response (Dudley, 
Wunderlich et al. 2002). However, generation and expansion of antigen specific TILs to clinically 
relevant numbers is technically challenging due to very limited number of tumor antigen specific 
T cells. Another limitation in regards to TILs is the fact that not in all tumors tissues TILs can be 
found or transferred in ex vitro culture systems.  
1.8 Re-directed T cells 
An alternative to the TIL strategy is the use of gene therapy by cloning TCRs or chimeric 
antigen receptors (CAR) into vectors and express them in autologous T cells. These re-directed 
T cells recognize the antigen with the help of the new receptor resulting in the redirection of the 
T cells.  
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Figure 1-3: Generation of anti-tumour T cells 
A tumor is excised and multiple individual cultures are established, separately grown and assayed for 
tumor specific T cells. Cultures with high anti-tumor reactivity are expanded to large number (>10
10
 cells) 
and re-infused into the patient (Rosenberg, Restifo et al. 2008) . 
1.8.1  Chimeric Antigen Receptor (CAR) 
The main drawback of adoptive T cell therapy is that tumors frequently lose antigen expression 
by down regulating MHC expression (Yadav, Ngolab et al. 2009), which makes the use of 
recombinant re-directed T cells an attractive approach. T cells can be re-directed using genes 
that encode monoclonal antibody chains or TCR like antibodies selected from phage display 
library (Held, Matsuo et al. 2004). These recombinant immunoreceptors are also known as 
chimeric antigen receptor (CAR). The idea of designing an chimeric antigen receptors came 
from the basic experiments performed in the early 1990`s, demonstrating that recombinant 
receptors made by fusing antibody domains with TCRβ, could direct the T cell activation 
independent of TCR-MHC interaction (Eshhar, Waks et al. 1993). The generation of CARs has 
been developed as a tool to re-direct T cells to target surface expressing tumor antigens to 
overcome immune surveillance mechanism by which tumors escape from endogenous T cells 
by losing MHC molecules. CARs are composed of an antigen recognizing region (mostly scFv) 
mainly derived from a monoclonal antibody fused with intracellular T cell signaling domains and 
transmembrane domain for optimal cell surface expression (Hombach, Wieczarkowiecz et al. 
2001; Heuser, Hombach et al. 2003). 
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Figure 1-4:  A  Natural and synthetic antigen receptors (Schamel and Reth 2012). B Schematic 
representation of a typical chimeric antigen receptor(Kershaw, Teng et al. 2005).  
1.8.2 T-cell Receptor (TCR) 
Antigen expressing target cells are recognized by a T cell with the help of special T cell 
receptors (TCR) expressed on the cell surface. TCRs are heterodimers composed of two highly 
variable α and βchains, paired with each other and the amino acid sequences of both α and β 
chains are responsible for antigen specificity (Viola and Lanzavecchia 1996). Tumor specific re-
directed T cells can be established by identifying and isolating TCRs from the T cells clones 
generated for defined target antigen (Abad, Wrzensinski et al. 2008). Recent molecular biology 
techniques allow for cloning of the genes that encode α and β chains of the antigen specific 
TCRs by using viral vectors (Sadelain, Riviere et al. 2003). In order to generate functionally 
competent re-directed T cells, both TCRα and β chain should be expressed efficiently. Optimal 
expression and pairing of both TCRα and β chains can be achieved by linking both chains to 2A 
ribosomal skip peptide. Cloning of antigen specific TCRs allows for re-directed T cells to 
respond antigen expressing tumor cells. The main disadvantage with α and β chain transfer is 
the miss-pairing with endogenous TCR chains (Kuball, Dossett et al. 2007). This miss-pairing 
may lead to reduced T cell activation and unintended autoimmune reactivity. Other draw-backs 
with the αβ TCR based re-directed T cells therapy is restriction to single HLA epitope. 
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Furthermore, TCRs cannot target whole proteins expressed on cell the surface and non-protein 
tumor antigens (Hiasa, Hirayama et al. 2008). 
 
 
 
Figure 1-5:  Re-directing T cells specificity by insertion of genes encoding a TCR or CAR (Turtle and 
Riddell 2011). 
1.8.3 Ligand 
In addition, ligands have also been shown to be useful for the use of TCRs and monoclonal 
antibodies to re-direct T cells (Lehner, Gotz et al. 2012; Morgan, Johnson et al. 2012). This is 
especially a powerful tool for the destruction of tumor vasculature. Recruiting of new blood 
vessels is the main requirement for the growth of solid tumors and, thus, inhibition of 
angiogenesis by using monoclonal antibodies or small molecules that interfere in their formation 
showed promising data (Muniappan, Banapour et al. 2000). An alternative strategy is to 
completely destroy the newly formed blood vessels by targeting endothelial growth factor 
receptors with their ligands or monoclonal antibodies conjugated with toxins. Using ligands as a 
target-binding moiety for constructing CARs, complete destruction of tumor vasculature could 
be achieved (Niederman, Ghogawala et al. 2002; Kahlon, Brown et al. 2004).  
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1.8.4 Signalling via chimeric antigen-receptor 
CAR construction requires four key components: An antigen specific moiety, an extracellular 
spacer molecule, a transmembrane domain and, finally, intracellular T cell signaling molecules. 
In general, an antigen specific moiety is a scFv derived from a tumor specific or tumor 
associated antigen specific monoclonal antibody. In some cases, ligands also are used for 
cloning CARs to target tumor vasculature. The architecture of a scFv is composed of a variable 
light (VL) and variable heavy (VH) chain of the monoclonal antibody joined by a flexible linker. A 
hinge or extracellular spacer molecule provides flexibility and accessibility for the scFv or 
binding molecule. Most commonly used extracellular spacer molecules are immunoglobulin 
fragment crystallizable regions (Fc) or extracellular domains of the CD8α or CD28 molecule, 
respectively. Transmembrane domains are usually derived from the most proximal molecule of 
the intracellular signaling domain. Primarily signaling domains derived from the CD3ζ (ITAM) 
chain or FcεRIγ are used. However, CD3ζ intracellular signaling domains have been shown to 
provide superior in vivo anti-tumor efficacy than FcεRIγ (Hombach, Wieczarkowiecz et al. 2001; 
Heuser, Hombach et al. 2003). CARs containing a single CD3ζ domain as intracellular signaling 
molecule are called first generation CARs. Although, first generation CARs can mediate 
cytotoxicity in vitro, they fail to confer T-cell sustainability for longer periods in vivo. It is known 
that for fully activated T cells, a co-stimulatory signal is required via CD28-B7 interaction in 
addition to CD3ζ signaling. Incorporation of a CD28 co-stimulatory intracellular domain in CARs 
resulted in sustained proliferation of re-directed T cells in vitro and in vivo. These CARs are 
called second generation CARs (Harding, McArthur et al. 1992; Chambers and Allison 1997; 
Finney, Akbar et al. 2004). Third generation CARs were developed with three different 
intracellular signaling domain molecules. Most commonly used third intracellular signaling 
molecules are OX40 and CD137 (4-1BB). Third generation CARs have been shown to increase 
proliferation of re-directed T cells and secretion of IL-2 in vitro (Till, Jensen et al. 2012).  
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Figure 1-6: Schematic representation of the different generation s of CARs 
1G, first generation, 2G, second generation, 3G, third generation CAR. The scFv is highlighted in green, 
while the different components of TCR signal transduction machinery are highlighted in red (CD3ζ 
chain/ZAP 70), blue (CD28/PI3K) and yellow (4-1BB or OX40/TRAF) (Casucci and Bondanza 2011). 
1.8.5 Clinical use of re-directed T cells 
The critical evaluation of re-directed T cells in vitro and several preclinical models have shown 
promising results encouraging the use of re-directed T cells in adoptive T cell transfer in clinics. 
First successful anti-tumour responses with re-directed T cells were observed in patients treated 
with anti-MART TCR re-directed T cells (Morgan, Dudley et al. 2006). In this study, two of the 
fifteen patients demonstrated regression of metastatic melanoma lesions after one year of 
infusion of the circulating re-directed T cells. This was the first clinical evidence that showed that 
gene modified re-directed T cells can mediate anti-tumor effects. A recent clinical trial with NY-
ESO-1 specific TCR transduced re-directed T cells have showed promising results in melanoma 
and synovial cell sarcoma patients expressing the NY-ESO-1 antigen (Robbins, Morgan et al. 
2011). In this study, two of 11 patients showed complete regression. Phase I clinical trials with 
first generation CARs have shown very little anti-tumor activity and poor persistence after 
infusion of re-directed T cells. First promising clinical responses were observed with second 
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generation CARs targeting CD19 antigen in a patient with chronic lymphocyte leukemia (van der 
Bruggen, Traversari et al. 1991; Shankaran, Ikeda et al. 2001; Yadav, Ngolab et al. 2009; 
Porter, Levine et al. 2011; Robbins, Morgan et al. 2011; Schreiber, Old et al. 2011; Till, Jensen 
et al. 2012). Currently, several clinical studies are being evaluated with second and third 
generation CAR re-directed T cells (www.clinicaltrial.gov; NCT00840853, NCT00673829)  
1.8.6 Side effects 
No clinical evidence has been documented for insertional mutagenesis with viral mediated gene 
transfer in re-directed T cells (Nicholson, Ghorashian et al. 2012) in retroviral insertional 
mutagenesis in stem cell therapy for X-linked SCID (Hacein-Bey-Abina, Von Kalle et al. 2003). 
The main safety issues with TCR re-directed T cells are pairing of newly introduced TCRs with 
endogenous TCRs, which may result in unknown specificity. However, studies with TCR re-
directed T cells mainly focused on preventing miss-pairing by engineering TCRs. Major concern 
with CAR re-directed T cells is the selection of the target antigens, since the majority of the 
tumor associated antigens (TAAs) though are over-expressed on tumor cells, however, have 
been observed also to have basal expressed on normal tissues. More recently, a clinical study 
with carbonic anhydrase IX (CA IX) specific CARs induced adverse effects (Lamers, Sleijfer et 
al. 2006; Lamers, Willemsen et al. 2011). In this study, patients with metastatic renal cell 
carcinoma (RCC) were treated with anti-CA IX CAR re-directed T cells. Some of them have 
developed severe liver toxicity because of T cells targeting the CAIX antigen also present in bile 
ducts (Lamers, Sleijfer et al. 2006). Second and third generation CAR re-directed T cells have 
induced signals which are intended to prolong survival and enhance proliferation upon antigen 
encounter. Due to the basal expression of antigen in normal tissue like described for HER2/neu, 
the encounter of antigen with CAR re-directed T cells can cause on-target off side adverse 
effects (Morgan, Yang et al. 2010). All these data taken together suggest that selection of the 
target antigen is the most crucial step in the development of CAR mediated adoptive T cell 
therapy.  
1.8.7 Therapeutic efficacy 
There is a rapidly growing number of clinical trials testing the concept of adoptive T cell therapy 
as a treatment option in cancer patients who have not responded to conventional therapies. 
Genetically engineered TCRs that prevent miss-pairing with endogenous TCRs, selection of 
different T cell subtypes and generation of second and third generation CARs have improved 
the scope of adoptive T cell therapy with re-directed T cells (Kohn, Dotti et al. 2011). Through 
technical improvement leading to reduced miss-pairing with endogenous TCRs and improved 
affinity for the antigen are additional advantages for the TCR re-directed T-cell therapy (Ferrara, 
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Reddy et al. 2010). Lymphocyte depletion prior to infusion of re-directed T cells have shown to 
improve anti-tumour effect in both preclinical and clinical settings (Restifo, Dudley et al. 2012) 
1.9 Expansion of T cells 
Several different approaches have been developed to generate tumor specific T cells. However, 
effective clinical response of TILs or re-directed T cells always depends on the number and 
quality of T cells generated in vitro. Major limiting factor is the large-scale number required to 
overcome inhibitory mechanism in the tumor microenvironment. Therefore, strategies allowing 
large-scale expansion of functionally intact re-directed T cells under GMP conditions have to be 
developed. T-cell activation and proliferation are mainly mediated by the CD3/TCR complex and 
co-stimulatory molecules such as CD28 and the signals are mainly provided by antigen 
presenting cells (APCs) (Durai, Krueger et al. 2009). Recently, several methods have been 
proposed to increase the number of tumor-specific T cells, which rely on the stimulation with 
antigen presenting cells pulsed with specific peptide, artificial antigen presenting cells or the 
polyclonal stimulation using either lectins or anti-CD3 plus anti-CD28 antibodies, respectively (Li 
and Kurlander 2010; Brimnes, Gang et al. 2012). Polyclonal stimulation with anti-CD3 plus anti-
CD28 results in the expansion of all cells (tumor-specific and polyclonal T cells) leading to large 
cell numbers with unknown specificity bearing the risk of off-target toxicity. The expansion of T 
cells with antigen presenting cells is technically challenging, more difficult to standardize and, 
therefore, not a straightforward GMP approach. 
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2 Aim of the thesis 
 
The aim of this thesis is to analyse T cells expressing a chimeric antigen receptor (CAR) derived 
from a TCR like antibody targeting NY-ESO-1 in regards to functional consequences of the 
interaction between the CAR and the antigen. Immunotherapy using re-directed T cells has 
emerged as a powerful tool for the treatment of cancer. The Cancer-Testis (CT) antigen NY-
ESO-1 is expressed in a variety of cancers but limited in expression on normal cells. NY-ESO-1 
protein has been used as a target for different cancer immunotherapies like peptide vaccination 
and adoptive transfer of antigen specific re-directed T cells. In vitro generation of chimeric 
antigen receptor (CAR) re-directed T cells with defined antigen specificity is an established 
method for cancer immunotherapy. However, selection of target antigens and characterization 
of CAR re-directed T cells is crucial for successful clinical outcomes. For better clinical efficacy, 
CARs have to be expressed efficiently on re-directed T cells and should have sufficient affinity 
to their target antigen but recognize only few molecules of endogenously processed peptides on 
the tumor cell surface without cross-reactivity. Previously, our group has been successful in 
selecting Fab molecule specific for the HLA-A2/NY-ESO-1157-165 peptide using a phage display 
library. The objective of this study was to determine the relevance of CAR affinities in 
generating re-directed T cells specific for NY-ESO-1 positive tumors and the feasibility of using 
anti-idiotypic Fab molecules for the selective expansion of anti-NY-ESO-1 CAR re-directed T 
cells in sufficient numbers for adoptive transfer. In order to determine the interaction between 
the peptide specific anti- NY-ESO-1 CAR and the NY-ESO-1 antigen and the resulting cellular 
processes following goals were specified. 
 Expression of anti-NY-ESO-1 CAR constructs with different affinities that recognize HLA-
A2/NY-ESO-1157-165 peptide on T cells 
 Characterization of re-directed T cells in vitro 
 Characterisation of CAR re-directed T cell activation in respect to antigen density 
 Anti-idiotypic Fab antibody dependent expansion of CAR re-directed T cells 
 Phenotypical and functional analysis of anti-idiotypic Fab antibody expanded CAR re-
directed T cells in vitro 
 Anti-tumor efficacy of in vitro expanded re-directed T cells in vivo 
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3 Material and Methods 
3.1 Equipment 
Agarose Gel Documentation BioDoc-It Imaging System UVP, Upland, USA 
Autoclave V-100 Systec, Hünenberg , 
Switzerland 
Blotting apparatus Trans-Blot SD semi-Dry 
Transfer cell 
Bio-Rad, Hercules 
USA 
Cell counter CASY Cell Counter Model TT Roche Innovatis, 
Bielefeld, Germany 
Centrifuges Centrifuge 5804R 
Centrifuge 5810R 
Centrifuge 5415D 
Eppendorf, Hamburg, 
Germany 
Flow cytometers FACScan 
FACSCalibur 
FACSCanto II 
BD Biosciences, San Jose, 
USA 
Magnetic-activated cell 
sorting 
MACS multistandard &quadro 
MACS 
Miltenyi Biotec, Bergisch 
Gladbach, Germany 
PCR cycler T300 Thermocycler Biometra, Göttingen, 
Germany 
Plate reader Wallac Victor2 1420 
Multilabel Counter 
Perkin Elmer, Waltham, USA 
Shaker system Multitron 2 Infors HAT, Bottmingen, 
Switzerland 
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Microscope Polyvar 2 Leica reichert jung, 
Heerbrugg, Switzerland 
Spectrometer BioPhotometer Eppendorf, Hamburg, 
Germany 
Water Purification Milli-Q Gradient System Millipore, Bedford, USA 
Western blot detection unit ChemiDoc-It Imaging System 
With BioChemi HR Camera 
UVP, Upland, USA 
 
3.2 Kits 
QIAGEN Plasmid Maxi Kit QIAGEN, Hilden, Germany  
QIAprep Spin Miniprep Kit QIAGEN, Hilden, Germany  
QIAquick Gel Extraction Kit QIAGEN, Hilden, Germany 
MycoAlert Mycoplasma Detection Kit Lonza Cologne GmbH, Cologne,  
Germany 
BD Cytofix/Cytoperm Kit BD Biosciences, San Diego, USA  
BD OptEIA Set Human IFN BD Biosciences, San Diego, USA 
BD OptEIA Set Human IL-2 BD Biosciences, San Diego, USA 
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3.3 Buffers 
TAE 2 mM 
0.25 mM 
0.5 mM   
TRIS Ultra 
Acetic acid 
EDTA 
PBS 
 
150 mM 
10 mM 
1.5 mM 
NaCl 
Na2HPO4 
KH2PO4 
0.05 % PBST 0.05 % (v/v) Tween20 
99.95 % (v/v)PBS 
Flow cytometry buffer 2 % (v/v) 
0.01 % (w/v) 
5 mM 
1 l 
FBS, heat inactivated 
Sodium azide 
EDTA 
PBS 
Blocking solution 
 
10 % (v/v) 
90 % (v/v) 
FBS, heat inactivated 
PBS 
TE 10 mM 
1  mM 
TRIS Ultra 
EDTA 
Adjust to pH 8 
5X SDS loading buffer 0.28 M 
1 % (w/v) 
30 % (v/v) 
0.0012%(w/v) 
5.5 % (v/v) 
TRIS Ultra 
SDS 
Glycerol 
Bromophenol blue 
Β-mercaptoethanol 
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1.5 M TRIS/SDS pH 8.8  1.5 M 
0.4 % (w/v) 
TRIS Ultra 
SDS 
Adjust to pH 8.8 
0.5 M TRIS/SDS pH 6.8 0.5 M 
0.4 % (w/v) 
TRIS Ultra 
SDS 
Adjust to pH 6.8 
12% (v/v) running gel 35 % (v/v) 
40 % (v/v) 
25 % (v/v) 
0.01 % (v/v) 
0.0005 % (v/v) 
dH20 
Acrylamide (30 % ) 
1.5 M TRIS/SDS pH 8.8 
APS 
TEMED 
5% (v/v) stacking gel 61 % (v/v) 
13 % (v/v) 
25 % (v/v) 
0.01 % (v/v) 
0.0007 % (v/v) 
dH20 
Acrylamide (30 %) 
0.5 M TRIS/SDS pH 6.8 
APS 
TEMED 
SDS running buffer 25 mM 
0.1% (w/v) 
200 mM 
TRIS Ultra 
SDS 
Glycine 
 
Coomassie destain 
 
45 % (v/v) 
10 % (v/v) 
45 % (v/v) 
 
Methanol 
Acetic acid (99%) 
dH2O 
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Western blot transfer buffer 25 mM 
190 Mm 
20 % 
TRIS Ultra 
Glycine 
Methanol 
5X DNA loading dye  50% (v/v) 
50 % (v/v) 
0.4 % (v/v) 
TAE 
Glycerol 
Orange G 
   
3.4 Antibodies 
Human OKT3 eBioscience, San Diego, USA 
Human CD28 (co-stimulatory) eBioscience, San Diego, USA  
 
Anti-human CD8-FITC eBioscience, San Diego, USA 
Anti-human IgG-PE Southern Biotech, Birmingham, USA 
Biotin-AffiniPure F(ab’)2 fragment goat anti-
human IgG (H+L) 
Jackson Immuno Research, Suffolk, UK 
Anti-human CD8 microbeads Miltenyi Biotec, Bergisch Gladbach,  
Germany 
Anti-human HLA-A, B, C-FITC Biolegend, San Diego, USA 
Mouse IgG2a, қ – FITC Isotype control Biolegend, San Diego, USA 
Anti-human IgE antibody Biolegend, San Diego, USA 
Anti-human CD62L-FITC BD Biosciences, San Jose, USA 
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Anti-human CD45RA-PB Biolegend, San Diego, USA 
Anti-human IFNγ-FITC BD Biosciences, San Jose, USA 
Anti-human TNFα-APC Biolegend, San Diego, USA  
Anti-human IL-2-PB Biolegend, San Diego, USA  
 Mouse monoclonal penta –His antibody QIAGEN, Hilden, Germany 
Mouse Anti-NY-ESO-1 clone E978 Invitrogen Corporation, Camarillo, 
USA  
 
3.5 Tetramer 
PE-conjugated HLA-A2/NY-ESO-1 157-165  
tetramer 
LICR, Lausanne, Switzerland 
 
3.6 Fab molecules 
Anti-idiotype Fab A4 and H6 In house, Zurich, Switzerland 
Control Fab (B1) In house, Zurich, Switzerland 
 
3.7 Cytokines 
Recombinant human IL-2 Immuno Tools, Friesoythe, Germany 
Recombinant human IL-15 Immuno Tools, Friesoythe, Germany 
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3.8 Peptides  
Primer designation Primer designation 
NY-ESO-1 157-165 peptide  SLLMWITQV 
Influenza matrix protein 58-66  GILGFVFTL 
 
3.9 Enzymes 
Restriction enzyme NcoI New England BioLabs, Ipswich, USA 
Restriction enzyme NcoI New England BioLabs, Ipswich, USA 
Streptavidin-Horse Radish Peroxidase BD Biosciences, San Diego, USA 
 
3.10 Plasmids and bacteria 
3M4E5-CD28/CD3ζ 
(1046wt)  
or 
anti-NY-ESO-1 CAR 
 
Expression cassette codes for a fusion protein 
consisting of a Lқ-leader sequence, the wt 
3M4E5 scFv recognizing the HLA-A*02:01/NY-
ESO-1157-165 complex, a human CH2CH3 IgG 
 
Stewart-Jones et 
al., 2009 
T1-CD28/CD3ζ(# 
1190) or  
anti-NY-ESO-1 CAR-
T1 
Expression cassette codes for a fusion protein 
consisting of a Lқ-leader sequence,  T1 scFv 
recognizing the HLA-A*02:01/NY-ESO-1157-165 
complex, a human CH2CH3 IgG domain and a 
 
 
Stewart-Jones et 
al., 2009 
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BW431/26-CD28/CD3ζ 
(#607) or anti-CEA 
CAR 
 
Plasmid coding for a CEA recognizing chimeric 
Expression cassette codes for a fusion protein 
consisting of a Lқ-leader sequence, a scFv 
recognizing carcinoembryonic antigen (CEA), a 
human CH2CH3 IgG domain and a CD28/CD3ζ 
 
Kind gift from Prof. 
Abken, Cologne, 
Germany 
pCOLT-GalV (#392)  
Helper plasmid 
 
Retroviral helper plasmid coding for GALV env 
protein 
 
Kind gift from Prof. 
Abken, Cologne, 
Germany 
pHIT60 (#393)  Helper 
plasmid 
 
Retroviral helper plasmid coding for MLV gag 
and MLV pol protein 
 
Kind gift from Prof. 
Abken, Cologne, 
Germany 
pCES1 plasmid pCES1 containing the variable domains of HC 
and LC fragments of selected anti-idiotypic Fab 
antibodies A4 and H6 
Kindly provided by 
Dyax, MA, USA 
 
3.11 Media for bacteria  
LB medium  10 g 
5 g 
5 g 
1 L 
Tryptone 
Yeast extract 
NaCl 
dH2O 
LB-AMP LB medium with 100 µg/ml 
ampicillin 
Sigma, St.Louis, USA 
LB-Amp Plates LB medium with 1.5 % (w/v) 
Difco agar 
BD, Sparks, USA 
2xTY 16 % (w/v) 
10 % (w/v) 
BactoTM Tryptone 
yeast extract 
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5 % (w/v) NaCl 
2xTY-AG  
0.1 mg/ml 
2 % (w/v) 
2xTY 
ampicillin 
glucose 
2xTY-AG agar plates  
1.5 % (w/v) 
2xTY-AG 
DifcoTM Agar 
 
3.12 Bacterial strain 
One shot TOP10 Chemically Competent 
E.coli 
Invitrogen, Karlsbad, USA 
Premade Z-competent E.coli cells (TG-1) Zymo Research, Irvine, USA 
3.13 Primers 
Primer designation Primer sequence  
pCES fwd_LC 5' – AGC GGA TAA CAA TTT CAC ACA GG - 3' 
pCES rev_HC 5' – GGA AGT AGT CCT TGA CCA - 3' 
Fwd-NcoI-Part1Lka CGT ACC ATG GAT TTT CAG TGT CAG ATT TTC AGC 
 TTC TTC ATG CTA ATC AGT GCC TCA GTC ATA ATG 
TC 
Rev-BamH1-3M4E5 GAT AGG ATC CAC TGT GGG GTT GG 
 
3.14 Cell culture media and cell lines 
All Cell lines were maintained at 37 °C in a CO2 incubator. Cell culture reagents were 
purchased from Gibco/Invitrogen (Carlsbad, USA) and Merck (Darmstadt, Germany). 
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3.14.1 Cell culture media 
Fetal Bovine Serum (FBS) 
Heat inactivated at 56 °C for 30 min 
Gibco, Carlsbad, USA 
RPMI 1640 media with Glutamax Gibco, Carlsbad, USA 
Hygromycine B Gibco, Carlsbad, USA 
Pencillin/Streptomycine Gibco, Carlsbad, USA 
0.05 % Trypsin-EDTA Gibco, Carlsbad, USA 
Dimethylsulfoxide (DMSO) Merck, Darmstadt, Germany 
 
3.14.2 Cell line 
293T  Derived from 293 cells, 
carries the SV40 large T 
antigen    
Kind gift  from Prof. Abken, 
Cologne, Germany 
T2-1B Minigene-transfected T2 cell 
line expressing NY-ESO-1157-
165/HLA-A2 complex 
Held et al., 2004 
T2-1C Minigene-transfected T2 cell 
line expressing NY-ESO-1155-
163/HLA-A2 complex 
Held et al., 2004 
U266 Human multiple myeloma cell 
line, secrete hIgE molecules 
Kind gift from Prof. Dr. U. 
Keilholz, Charitè, Berlin, 
Germany 
MCF7 Breast cancer cell line  Kind gift from Prof. M.Van 
den Broek, Zürich, 
Switzerland 
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3.15 Mice 
Inbred NOD-SCIDγc -/- (NSG) mice were maintained under specified pathogen-free conditions in 
our Institutional Animal Care unit. 6-8 weeks old NSG mice were used for in vivo experiments 
3.16 Software 
GraphPad Prism V 5.01 for windows GraphPad Software, San Diego, USA 
Cellquest Pro 4.0.2 BD Biosciences, San Jose, USA 
FACSdiva BD Biosciences, San Jose, USA 
FlowJo 7.2.5 Tree Star, Ashland, USA 
  
3.17 Bacterial methods 
3.17.1 Transformation of competent E. coli cells 
The ligation mixture was added to 1 vial of commercially available TOP10 competent E. coli 
cells and incubated for 15 min on ice, followed by heat-shock for 45s at 42 °C and immediately 
placed on ice for 1 min. 250 µl SOC medium was added followed by shaking for 1 hour at 37 °C 
at 250 rpm. 
3.17.2 Growth of bacteria on agar plates  
50 µl of freshly transformed E.coli cells or glycerol stock diluted in LB-Amp medium was plated 
on LB-Amp agar plates. Plates were incubated over night at 37 °C. 
3.17.3 Growth of bacteria in suspension 
For small scale bacterial expansion, single colony from LB-Amp agar plate or 15 µl of bacterial 
glycerol stock was inoculated in 5 ml of LB-Amp media and incubated over night at 37 °C in a 
shaker (200 rpm) 
3.17.4 Glycerol stocks of bacteria 
15 % v/v of glycerol was mixed with overnight grown bacterial culture in 2 ml cryotube and 
stored at -80 °C. 
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3.18 Molecular biology techniques 
3.18.1 Purification of plasmid DNA from E.coli 
Large amounts of plasmid DNA required for transient transfections was purified from overnight 
grown TOP10 strain carrying plasmid of interest. QIAGEN plasmid Maxi Kit was used to extract 
DNA was extracted from QIAGEN plasmid Maxi Kit according to manufactures protocol. DNA 
was eluted with sterile molecular biology grade water. DNA concentration was determined by 
using Nano Drop. 
 
3.18.2 Agarose gel electrophoresis 
To check the purity of the plasmid DNA, 0.7-1 % (w/v) agarose (promega, Madison, USA) gel 
was prepared with TAE buffer, 10 µg/ml of ethidium bromide was added to the gel. Purified DNA 
samples were mixed with DNA loading dye and 100 bp or 1 kb DNA ladder was used as size 
standard. 180-100 V of current was applied to the gel and the separation was monitored under 
UV light. 
3.18.3 Expression and purification of anti-idiotypic Fab antibodies 
Overnight grown E.coli TG-1 bacterial cultures expressing anti-idiotypic Fab antibodies were 
inoculated at 1:100 dilutions in 1 l of fresh 2xTY broth, containing 100 µg/ml ampicillin and 0.1 
% glucose and grown at 37 °C. Cells were induced with IPTG when OD 0.8-1 was reached and 
continued to grow at 30 °C for 4 h. Cells were then centrifuged at 4000 rpm for 15 min. and peri-
plasmic proteins isolated by osmotic shock. His-tag containing Fabs were purified by using 
Talon Metal affinity resin (Clontech, Mountain View, CA). Purity of Fab was accessed by 12 % 
SDS gel electrophoresis. 
3.18.4 SDS Polyacrylamide gel electrophoresis 
 2 µg of purified Fab antibody molecules in 20 µl were mixed with 5 μl of 5X loading buffer and 
denatured at 95 °C for 5 min. proteins were first collected in a 5 % (v/v) stacking gel at 45 mA 
and subsequently separated according to their molecular weight in 12 % running gel at 70 mA 
using running buffer as previously described in buffer section. Precision Plus ProteinTM dual 
color protein marker was used as molecular weight standard. Gels were stained with 
Coomassie staining solution and gels were de-stained with Coomassie de-stain until protein 
bands were visible.  
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3.18.5 Western blotting 
For the detection of proteins, unstained gels and PROTRAN nitrocellulose membrane (0.45 μm 
pore size) were equilibrated in transfer buffer and proteins from separated gel were blotted 
using a Trans-blot SD apparatus for 30 min at 12 V per gel. For the detection of designated 
target proteins, membrane was blocked with 4 % MPBS for 1h at room temperature. Membrane 
was incubated with specific antibodies in PBS for 1h; membrane was washed with 0.1 % PBS-T 
for 10 min and incubated with anti-mouse/HRP conjugate for 1 hour. After 10 min washing, 
detection of protein was performed using Amersham ECL western blotting detection reagents.  
3.19 Cell culture and immunological methods 
3.19.1 Cultivation of cell lines 
293T, U266 and MCF7 cells were cultivated in R10 media (RPMI 1640 GlutaMax supplemented 
with 10% FBS, 50 U/ml penicillin and 50 µg/ml streptomycin). NY-ESO-1 peptide transfected 
HLA-A2 positive TAP deficient T2 cell lines T2-1B (HLA-A2/NY-ESO-1 157-165) and T2-1C 
(HLA-A2/NY-ESO-1 155-163) were cultured in R10 media along with 2.5 µg/ml hygromycine 
B(Held, Matsuo et al. 2004). All cells were cultured at 37 °C and 5 % CO2. 293T and MCF7 cell 
lines from culture flasks were detached by using PBS-1 mM EDTA. Cells were collected from 
the flask and centrifuged at 1500 rpm for 5 min. Cells were re-suspended in fresh culture 
medium. 10X106 cells were frozen in 1.5 ml cryotube in 1 ml of freezing media (90 % FBS (v/v) 
10% DMSO (v/v)). 
3.19.2  Determination of cell number 
Cell number of all cell lines and primary cells were determined by CASY cell counter+ analyser 
system model TT (Roche Innovatis, Bielefeld, Germany). 50 μl of sample cells were mixed with 
10 ml of CASYton solution and analysed with the cell counter. 
3.19.3 Mycoplasma test 
Mycoplasma contamination was tested for every cell line using MycoAlert Mycoplasma 
detection Kit (Lonza Cologne GmbH, Cologne, Germany) in three months.  
3.19.4 Purification of human CD4+ and CD8+ T cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors by density 
gradient centrifugation using Ficoll and PBMCs were washed with cold Phosphate-buffer saline 
(PBS) containing 0.5 % (w/v) FBS and 2 mM EDTA. CD4+ and CD8+ T cells were positively 
Material and Methods 
Gopinadh Jakka  Page 28 
selected using the CD4+ and CD8+ T cell isolation kits (Miltenyi Biotech, Germany) according to 
manufacturer’s instruction. 
3.19.5 Activation of T cells 
Freshly isolated human T cells were stimulated with R10 media containing 100 ng/ml of anti-
human CD3 (OKT3) and 100 ng/ml anti-human CD28 mouse monoclonal antibodies along with 
400 IU of human recombinant IL-2.  
3.19.6 Generation of re-directed CD8+ anti-NY-ESO-1 T cells 
Redirected T cells were generated as described previously. In short, peripheral blood 
mononuclear cells (PBMCs) were isolated from healthy donors by density gradient 
centrifugation using Ficoll gradient. CD8+ T cells were negatively selected using the CD8+T cell 
isolation kit (Miltenyi Biotech, Germany) according to manufacturer’s instructions. Anti-HLA-
A*0201/NY-ESO-1157–165 (anti-NY-ESO-1 CAR) scFv fragment, flanked by NcoI and BamHI 
restriction sites were cloned into the pBullet vector containing human CD3ζ and CD28 signaling 
domains. The BW431/26-CD28/CD3ζ CAR construct that directly recognizes the 
carcinoembryonic antigen (CEA) served as control and was termed anti-CEA CAR. The 
retroviral transduction of CD8+ T cells with recombinant receptors was performed by co-culturing 
the polyclonally activated CD8+ T cells with transiently transfected 293T cells as described. After 
24h of co-cultivation, expression of recombinant receptors was monitored by flow cytometric 
analysis using PE-labeled anti-human IgG1, HLA-A*0201/NY-ESO-1157–165 tetramer labeled with 
PE and FITC-conjugated anti human-CD8 purchased from Biolegend (San Diego, CA). 
3.19.7 Peptide loading of T2 cells 
The NY-ESO-1 157-165 SLLMWITQV peptide (9v) or the influenza matrix protein (IMP) 58-66 
GILGFVFTL peptides were dissolved in DMSO to obtain 10 μg/ml concentration. For the loading 
of peptide T2 cells were washed two times with serum free RPMI and 50,000 T2 cells were 
incubated with different concentration of peptides for 2 h at 37 °C. After one wash, cells were 
incubated with anti-NY-ESO-1 T1 CAR re-directed CD8+ T cells. 
3.19.8 Intracellular cytokine staining (ICS) 
2X105 anti-NY-ESO-1 CAR re-directed CD8+ T cells were incubated either with T2-1B cells, T2-
1C cells or with medium alone (control) in the presence of 5 μg/ml Brefeldin A and 5 μg/ml 
monensin at 37 °C for 5 h. Cells were surface stained with anti-human CD8-PE-Texas Red and 
anti-human IgG-PE Southern Biotech (Birmingham, AL, USA) monoclonal antibodies for at 4 °C 
15 min. After surface staining, cells were washed with FACS buffer (FB; PBS + 2 % FCS + 40 
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mM EDTA + 0.05 % NaN3), fixed with 2% paraformaldehyde and permeabilized with 
permeabilization buffer (PB; FACS buffer + 0.1 % saponin). Cells were stained for intracellular 
IFNγ, TNFα and IL-2 with specific monoclonal antibodies (Biolegend, San Diego, USA) at 4 °C 
for 15 min. Samples were measured with a CyAn ADP9 flow cytometer (Beckman Coulter, Brea, 
CA, USA) and results were analyzed using FlowJo analysis software. 
3.19.9 Colorimetric analysis of cell cytotoxicity 
CD8+T cells were co-cultured in 96-well round bottom microtiter plates at different numbers 
(ranging from 2,500-20,000 CAR-positive T cells per well) with 10,000 HLA-A2/NY-ESO-1157–165-
positive cells (T2-1B) or control cells in 200 µl of R10 medium. After 24 h, XTT reagent (Cell 
Proliferation Kit II, Roche Diagnostics, Rotkreuz, Switzerland) was added to the cells and 
incubated at 37 °C for 30–90 min. Reduction of XTT to formazan by viable tumor cells was 
colorimetrically monitored. Maximal reduction of XTT was determined as the mean of 3 wells 
containing target cells only, and the background as the mean of 3 wells containing R10 medium. 
The non-specific formation of formazan due to the presence of effector cells was determined 
from triplicate wells containing effector cells in the same number as in the corresponding 
experimental wells. 
3.19.10 5-aza-2’ Deoxycytidine (DAC) treatment 
MCF7 (breast cancer) and U266 (multiple myeloma) cells were cultured in R10 medium. 1X106 
MCF7 and U266 Cells were plated in T25 culture flasks, followed by treatment with R10 media 
containing 10 μM of  5-aza-2’ Deoxycytidine (DAC) after 24 h, for  four times in a day, Control 
group was cultivated in the absence of DAC. DAC treatment was carried for three days and 
cells were cultivated in R10 medium (without DAC) for additional two days. Cells were then 
subjected to cytotoxic assay and IFNγ ELISA by co-culturing with anti-NY-ESO-1 T1 CAR re-
directed CD8+ T cells. 
 
3.19.11 Binding of anti-idiotypic Fab antibodies with anti-NY-ESO-1155–163/HLA-A*0201 
antibody 
A4 and H6 anti-idiotypic Fabs were coated on the surface of 96-well ELISA (Nunc, 
Langenselbold, Germany) plates at a concentration of 0.01 µg/µl in carbonate buffer (pH 9.5) at 
37 °C for 3-4 h. Unbound Fabs were removed by PBS (pH 7.4) washing. Wells were 
subsequently blocked with PBS plus 10 % FCS for 1 h at room temperature (RT). Anti- NY-
ESO-1155–163/HLA-A*0201 (3M4E5) or control hIgG antibodies at a concentration of 1 ng/µl were 
added to the anti-idiotypic antibody coated wells and incubated for 1 h at RT. Plates were 
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washed three times with PBS containing 0.05 % Tween-20 to remove unbound antibodies. 
Binding of the 3M4E5 antibody was accessed with HRP-labeled anti-human Fc specific 
antibody (ImmunoResearch, Suffolk, Great Britain) according to the manufacturer’s instructions. 
3.19.12 Surface Binding of Anti-Idiotypic Fab antibodies 
293T cells were transfected with the anti-NY-ESO-1 CARs as described previously (Schuberth, 
Jakka et al. 2012).  After 24 h, 105 anti-NY-ESO-1 CAR grafted 293T cells were washed twice 
with PBS (pH 7.5) containing 2 mM EDTA and 0.05 % FCS (FACS buffer). Cells were re-
suspended in 0.01 µg/ul anti-idiotypic Fabs in FACS buffer and incubated for 30 min at 4 °C. 
Cells were washed with FACS buffer and incubated with mouse anti-His tag monoclonal 
antibody (Qiagen, Hombrechtikon, Switzerland) for 30 min.  Followed by PE-labeled anti-mouse 
IgG1 antibody (Southern Biotech, Birmingham, AL). Binding of anti-idiotypic Fabs was analyzed 
by FACScan (BD Bioscience, San Diego, CA). Data were analyzed using FlowJo software (Tree 
Star, Asland, OR). 
3.19.13 Competition assay of binding of anti-idiotypic Fab molecules 
105 anti-NY-ESO-1 CAR CD8+ T cells were washed twice with FACS buffer. Anti-NY-ESO-1 
CAR re-directed CD8+ T cells were incubated with different concentrations of anti-idiotypic Fab 
A4 (1, 0.25, 0.03 μg/μl) for 15 min at RT, 1 μg/μl of irrelevant Fab served as control for anti-
idiotypic Fab. 10 µl of PE-labeled HLA-A*02:01/NY-ESO-1157-165 tetramer (0.002 μg/μl) was 
added to each sample. Tetramer alone served as a negative control. Tubes were incubated for 
5 min at RT. Cells were washed with FACS buffer and inhibition of tetramer binding was 
determined by fluorescent intensity measured by FACScan (BD Bioscience, San Diego, CA). 
Data were analyzed using FlowJo software (Tree Star, Asland, OR). 
3.19.14 Activation of anti-NY-ESO-1 CAR re-directed CD8+ T cells with anti-idiotypic or 
with HLA-A2 dimer pulsed with NY-ESO-1157-165 peptide 
2 to 200 nM anti-idiotypic Fab antibody or recombinant HLA-A2 dimer (BD Bioscience, San 
Diego, CA) were coated on 96 well cell culture plates at 37 °C for 3 h or at 4 °C overnight. 
Plates were washed with PBS to remove unbound molecules. 100 µl of 10 µM NY-ESO-1157-165 
peptide was added to the recombinant HLA-A2 coated wells that were subsequently incubated 
at 37 °C for 3 h. Plates were washed with PBS; 2 x 104 anti-NY-ESO-1 CAR re-directed CD8+ T 
cells were added to each well. After 24 h of stimulation, secretion of IFNγ was measured using 
an IFNγ ELISA kit (BD OptEIATM, San Diego, CA) according to the manufacturer's instructions. 
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3.19.15 Antigen-dependent expansion of anti-NY-ESO-1 CAR re-directed CD8+ T cells 
25 cm2 tissue culture flasks were coated with 2 µg/ml of anti-NY-ESO-1 CAR specific anti-
idiotypic Fab antibodies or control Fab (irrelevant Fab) molecules and incubated at 37 °C for 3-4 
h. 106 anti-NY-ESO-1 CAR positive re-directed CD8+ T cells were added to the flasks in 5ml of 
RPMI 1640 medium supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin 
and 2 mM L-glutamine (R10 medium) and 50 IU/ml of human recombinant (rh) IL-2. The 
medium was replaced with fresh R10 medium containing rh IL-2 (50 IU/ml) after 24 h of 
stimulation. For T2-1B mediated activation, 2.5x105 irradiated (γ-irradiation with 50 Gy) 
stimulator cells (T2-1B) were co-cultured as described above at a ratio of 4 to 1 (effector to 
target). Re-directed T cells were stimulated repetitively with irradiated T2-1B cells or anti-
idiotype antibody every 8 days. Increase in receptor positive cells was identified by surface 
staining with anti-human IgG antibody and the cell number was determined by counting viable 
cells on a weekly basis. 
3.19.16 Phenotyping of expanded re-directed CD8+ T cells 
Phenotype analysis of expanded anti-NY-ESO-1 T1 CAR redirected CD8+ T cells 0.5 x 106 
redirected T cells were washed with FACS buffer and surface stained with anti-human IgG-PE, 
CD8-PE-Cy7, CCR7-FITC and CD62L-APC; all the antibodies were used according to 
manufacturer’s instructions. Cells were washed and fixed with 2 % paraformaldehyde for 10 min 
at RT. After washing cells were re-suspended in FACS buffer and analyzed by flow cytometer. 
Flow cytometry analysis was performed using FACSCanto II. 
3.19.17 IgE ELISA 
The anti-tumor effect of the expanded anti-NY-ESO-1 T1 CAR re-directed CD8+ T cells was 
assessed by measuring tumor size and serum IgE levels. Blood was collected from mouse tail 
vein and serum was separated for measuring IgE protein levels. Maxisorp 96-well flat bottom 
plates (NUNC, Rochester, USA) were coated with 5 µg/ ml (100 µl/well) purified anti-human IgE 
antibody diluted in carbonate buffer (pH 9.6) and incubated at 3-4 h at 37 °C.  Unbound 
antibodies were removed by washing plates with washing buffer (PBS/0.05 % tween 20) and 
blocked with PBS containing 10 % FBS at room temperature (RT) for 1 h. After washing (three 
times), mouse serum samples and standard (purified human IgE protein) were added to the 
wells and incubated at RT for 1 h. Plates were washed 5 times and then incubated with 1 µg/ml 
of biotinylated anti-human IgG ,F(ab)2  specific antibody diluted in 10 % FBS/PBS for 1 h at RT.  
Plates were washed five times and 1 μg/ml of streptavidin-Horse Radish Peroxidase was added 
(1h at RT). Substrate was added after 5 times of washing and reaction was stopped using 2N 
H2SO4 (Sigma-Aldrich, St.Louis, USA) and measured at 450 nm. 
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3.19.18 Xenograft model 
In vivo anti-tumor functional studies: NOD-SCIDγc (null) (NSG) mice were bred and maintained 
under specific pathogen free conditions in house. Six to eight week old NSG mice were injected 
subcutaneously with 10X106 multiple myeloma U266 tumor cells with or without expanded anti-
NY-ESO-1 T1 CAR re-directed CD8+ T cells. Tumor growth was assessed by measuring serum 
IgE levels every week and tumor size was measured with the help of caliper in two 
perpendicular dimensions and the tumor volume was calculated using the formula: Tumor size 
in mm2=(length X width).  
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4 Results 
4.1 Re-directed T cells 
Previously, our group has selected a TCR like antibody (3M4E5) from a large phage display 
library that recognizes the HLA-A2/NY-ESO-1 157-165 peptide (Held, Matsuo et al. 2004). 
Selective mutation in the peptide binding region of two light chain amino acids of the 3M4E5 
Fab molecule enhanced the affinity by 20 fold (3M4E5-T1) in the range of 2-4 nM. In our group, 
chimeric antigen receptors (CARs) were constructed from the scFv of 3M4E5 (anti-NY-ESO-1 
CAR) and the 3M4E5-T1 (anti-NY-ESO-1 CAR T1) Fab molecules (Stewart-Jones, Wadle et al. 
2009). ScFvs were cloned into the optimized pBULLET retroviral vector in line with the CH2/3 
IgG domain and the CD28-CD3ζ domains (Hombach, Wieczarkowiecz et al. 2001). CD8+ T 
cells were positively selected from human PBMCs isolated from buffy coats to express the 
chimeric antigen receptors. For the generation of CAR gene carrying retrovirus, 293T cells were 
transiently transfected with the specific CAR expressing cassette along with two helper 
plasmids, one for the gag and pol protein of the retrovirus and the other one for env protein. To 
express the CARs in CD8+T cells, activated CD8+ T cells were co-cultured with transiently 
transfected 293 T cells. CARs were expressed in CD8+ T cells consisting of scFv derived from 
3M4E5 (anti-NY-ESO-1 CAR) and 3M4E5-T1 (anti-NY-ESO-1 CAR T1) linked to CH2/3 IgG-
CD28-CD3 ζ domains. Anti-CEA CAR (BW431/26-CD28/CD3ζ) re-directed CD8+ T cells were 
used as control (construct kindly provided by Prof. Abken) (Chmielewski, Hahn et al. 2012). The 
schematic representation of CAR constructs is shown in figure 1. 
 
Figure 4-1: Schematic representation of expression cassettes for the recombinant anti-NY-ESO-1 CARs 
and control immuno receptor anti-CEA CAR. 
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4.2 Transduction  
Expression of CARs on CD8+ T cell surface was assessed by surface staining of human 
immunoglobulin CH2/CH3 domains with anti-human IgG Fc specific mouse monoclonal 
antibodies using flow cytometry. 28-50 % of CD8+ T cells expressed the respective CAR on 
their cell surface (figure 2A). Antigen specific binding of anti-NY-ESO-1 CARs were measured 
by using a HLA-A2/NY-ESO-1 157-165 peptide tetramer-PE conjugate. Similar results were 
observed with tetramer staining as detected with anti-human IgG Fc specific antibody; whereas 
no binding of tetramer was observed in anti-CEA CAR expressing CD8+ T cells (figure 2B). This 
observation shows that surface expressed anti-NY-ESO-1 CARs specifically bind to the NY-
ESO-1 157-165 peptide in context with HLA-A2 molecule (Schuberth, Jakka et al. 2012). 
 
Figure 4-2: A surface expression of the grafted receptors on CD8+ T cells confirmed by flow cytometry 
analysis. Transduced CD8+ T cells were simultaneously incubated with PE-conjugated anti-human IgG1 
and FITC-conjugated anti-CD8 mAb. B Antigen specific binding confirmed by NY-ESO-1157-165/HLA-A2-
teramer-PE and FITC-conjugated anti-CD8 mAb. 
4.3 Characterization of target cells  
TAP deficient T2 cells were used to test for antigen-specific functionality of re-directed CD8 T 
cells. These cells express low amounts of MHC class 1 on the cell surface. Transfection of 
these T2 cells with minigenes encoding HLA-A2 peptide linked to ER signaling sequences 
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enhances the stable expression of HLA-A2 molecules on the cell surface (Zweerink, Gammon 
et al. 1993). For the stable expression of NY-ESO-1 peptides, T2 cells were transfected with 
minigenes, expressing the NY-ESO-1 157-165 peptide (T2-1B) or NY-ESO-1 155-163 (T2-1C), 
respectively. We analyzed the surface expression levels of HLA-A2 molecules on minigene 
transfected T2 cells. Results revealed similar levels of HLA-A2 expression on both peptide 
transfected T2 cells (Figure 3A). Next, we confirmed the expression of NY-ESO-1 157-165 
peptide in the context of HLA-A2 on the cell surface of transfected T2 cells using anti-NY-ESO-1 
(T1) Fab tetramer-PE, which is specific for HLA-A2/NY-ESO-1 157-165. We observed the specific 
binding of anti-NY-ESO-1 tetramers with T2-1B cells and no specific signal was observed with 
T2-1C cells (figure 3B). Furthermore, we analyzed the HLA-A2 and NY-ESO-1 expression on 
tumor cell lines: The multiple myeloma cell line U266 is known to be positive for HLA-A2 and 
expresses NY-ESO-1 protein. The breast cancer cell line MCF7 expresses similar levels of 
HLA-A2 on the cell surface and does not express NY-ESO-1 protein (figure 3C). These results 
were further confirmed by Western blot (figure 3D). With these different cell lines, antigen-
specific functionality could be tested in further experiments. 
 
 
 
 
 
 
 
 
 
  
 
Figure 4-3: Surface staining of minigene transfected T2 cells. A Surface expression of HLA-A2 was 
determined by staining of T2-1B (dashed line) and T2-1C (dotted line) with anti-human HLA-A2 FITC and 
isotype control antibodies. B Surface expression of NY-ESO-1 peptide in context of HLA-A2 was 
determined by staining with anti-HLA-A2/NY-ESO-1 157-165 tetramer-PE (T1). B T2-1B (dashed line) and 
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T2-1C (dotted line) cells were stained with anti-HLA-A2/NY-ESO-1157-165 tetramer-PE(T1). C Expression 
of HLA-A2 and NY-ESO-1 protein in U266 multiple myeloma cell line (dashed line) and MCF7 breast 
cancer cell line (dotted line ) was confirmed with anti-human HLA-A2 –FITC staining .D Western blot 
analysis of NY-ESO-1 protein expression in U266 and MCF7 cells. 
4.4 Characterization of re-directed T cells  
4.4.1 Polyfunctional analysis of re-directed T cells 
With help of the characterized cell lines, antigen-specific poly-functionality of the re-directed T 
cells was evaluated by intracellular cytokine staining. We co-incubated freshly transduced re-
directed anti-NY-ESO-1 CAR and anti-NY-ESO-1 CAR (T1) positive CD8+ T cells with T2-1B 
(antigen specific) T2-1C (control) for 4 hours. As shown in figure 4A, both CARs re-directed 
CD8+ T cells in a poly-functional manner. T cells secreted the cytokines IFNγ, TNFα and IL2 in 
an antigen specific manner. In contrast, no to basal activation was observed with control cells. 
We observed significant difference in cytokine production between antigen specific and control 
cell activation (figure B). 
 
Figure 4-4: Poly-functional analysis of CAR re-directed CD8+ T cells. Antigen specific cytokine secretion 
of anti-NY-ESO-1 CARs was determined by intracellular staining. Anti-NY-ESO-1 CAR and anti-NY-ESO-
1 CAR(T1) re-directed CD8+ T cells were incubated with T2-1B and T2-IC cells for 4 hours . A: dotplot 
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indicating percentage of IFNγ, TNFα and IL2 positive cells. B: Statistic analysis of N=3 experiments of 
cells secreting IFNγ, TNFα and IL2. 
4.4.2 Anti-NY-ESO-1 CAR expressing re-directed CD8+ T cells lysed the antigen 
expressing target cells and secreted cytokines.  
Since we demonstrated antigen-specific cytokine secretion of CD8 positive re-directed T cells, 
we aimed to demonstrate effector cell function. In order to demonstrate functional differences in 
the lysis between anti-NY-ESO-1 CAR and anti-NY-ESO-1 CAR (T1), we performed XTT based 
colorimetric cytotoxic assay to assess target cell lysis of NY-ESO-1 157-165 peptide expressing 
T2-1B cells as target and NY-ESO-1 155-163 peptide expressing T2-1C as control cells. We 
observed a significant increase in lysis of target cells (T2-1B) with anti-NY-ESO-1 CARs re-
directed CD8+ T cells when compared with control anti-CEA CAR re-directed T cells (figure 5A). 
We have not observed any significant lysis of T2-1C cells with any of the re-directed T cells 
(figure 5B). Furthermore, we observed a significant difference between wild type anti-NY-ESO-1 
CAR and affinity matured anti-NY-ESO-1 CAR (T1) at lower effector target ratios, which was not 
observed at higher effector target ratios (figure 5A). T cell activation marker IFNγ and granzyme 
B were measured in supernatants of these experiments. IFNγ and granzyme B secretion was 
observed specifically with T2-1B culture supernatants (figure 5C&E) in antigen specific manner. 
Only background levels were observed with T2-1C control cells and control anti-CEA CAR 
(figure 5D&F). 
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Figure 4-5: Comparison of anti-NY-ESO-1 wild type and affinity matured (T1) chimeric antigen 
receptor re-directed CD8+ T cells. A&B anti-NY-ESO-1 CAR, anti-NY-ESO-1 CAR (T1) and anti-CEA 
CAR re-directed CD8+ T cells were co-cultivated with minigene transfected T2 (TAP-deficient) cell lines 
T2-1B and T2-1C for 24h. T2-1B expressed NY-ESO-1157-165 /HLA-A2, whereas T2-1C expresses NY-
ESO-1155-163 /HLA-A2. Transduced cell populations were adjusted to obtain equal effector cell numbers. 
Viability of tumor cells was determined colorimetrically by a tetrazolium salt-based XTT assay after 24h. 
C&D IFN-gamma and E&F granzyme B secretion by CAR re-directed CD8+ T cells into the culture 
supernatant was determined by ELISA. 
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4.4.3 Anti-NY-ESO-1 TCR CAR activates both CD4+ and CD8+ T cells  
MHC restricted and co-receptor independent function of anti-NY-ESO-1 CAR (T1) was 
evaluated in purified populations of CD4+ and CD8+ T cells. The anti-NY-ESO-1 CAR (T1) and 
anti-CEA CAR re-directed CD4+ and CD8+ T cells were co-cultured with T2-1B and T2-1C cells 
for 24 h. Antigen specific IFNγ secretion was observed in both, CD4+ and CD8+ T cell 
populations and only background levels of cytokine secretion were observed with anti-CEA CAR 
and T2-1C cells (figure 6A&B), respectively. These results suggest that CARs generated from 
TCR like antibodies function in a MHC-restricted and co-receptor independent manner. 
Furthermore, the sensitivity of anti-NY-ESO-1 CAR (T1) re-directed T cells was analyzed by co-
culturing the re-directed CD4+ and CD8+ T cells with peptide pulsed T2 cells. IFNγ secretion 
was enhanced in a dose dependent manner in anti-NY-ESO-1 CAR (T1) re-directed CD4+ and 
CD8+ T cells whereas no IFNγ secretion was observed with control peptide (Flu) pulsed T2 
cells and with anti-CEA CAR re-directed T cells. These results indicate that increase in peptide 
density on cell surface increases T cell function (figure 6 C& D).  
. 
 
Figure 4-6: Anti-NY-ESO-1 CAR generated from TCR like antibody functions in re-directed CD4+ and 
CD8+ T cells in MHC restricted and co-receptor independent manner. Purified human CD4+ and CD8+ 
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T cells were re-directed with anti-NY-ESO-1 CAR (T1). A&B CD4+ and CD8+ T cell populations were co-
incubated with T2-1B and T2-IC cells for 24 hours. T cell activation marker IFNγ was measured in culture 
supernatant. C&D  T2 cells were pulsed with different concentration of NY-ESO-1 157-165 peptide and 
incubated with anti-NY-ESO-1 CAR(T1) re-directed CD4+&CD8+ T cells for 24 hours. IFNγ was 
measured from culture supernatants. 
4.4.4 5-aza-2-deoxycytidine (DAC) treatment enhances anti HLA-A2/NY-ESO-1157–165 
peptide specific re-directed CD8+ T cell effector function. 
In the previous experiment we have demonstrated that increased HLA-A2/NY-ESO-1157–165 
peptide-load augments killing of target cells (Figure 5-5). Therefore, we tested whether DAC 
treatment enhanced the anti-NY-ESO-1 CAR (T1) activity by increased peptide expression. We 
transduced CD8+ T cells with anti-NY-ESO-1 CAR (T1) and anti-CEA CAR as a control. DAC 
treated MCF7 cells specifically activated anti-NY-ESO-1 CAR (T1) re-directed CD8+ T cells only 
whereas no activation was observed with untreated MCF7 cells. The Multiple myeloma cell line 
U266 that constitutively expresses NY-ESO-1 protein were lysed even in the absence of DAC 
treatment. Moreover, DAC treatment enhanced the lysis significantly. No specific lysis was 
observed with control CAR re-directed T cell (figure7 A). We measured the T cell activation 
marker IFNγ in the culture supernatant of both DAC treated and untreated samples, specific 
IFNγ secretion was observed with DAC treated MCF7 cells and U266 cells, where IFNγ 
secretion was significantly increased in DAC treated U266 cells (figure7 B). These results 
indicate that increasing peptide density on cell surface with DAC-treatment enhanced the 
antigen specific function of re-directed T cells. 
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Figure 4-7: A. Treatment of the NY-ESO-1 positive multiple myeloma cell line (U266) and NY-ESO-1 
negative breast cancer cell line MCF7 with the demethylating agent 5-aza-2-deoxycytidineincreases 
(DAC). NY-ESO-1 expression thus enhancing the killing by NY-ESO-1157-165 specific anti-NY-ESO-1 CAR 
(T1) re-directed CD8+ T cells.B. Specific activation of anti-NY-ESO-1 CAR (T1) re-directed CD8+ T 
cellswas determined by measuring the IFN-gamma secretion in culture supernatant by ELISA. 
4.5 Expansion of re-directed T cells 
4.5.1 Selection and characterization of anti-idiotypic Fab molecules for antibody 
recognizing HLA-A*0201/NY-ESO-1157–165 (anti-NY-ESO-1) 
Since we showed that re-directed T cells were antigen-specifically activated by cells expressing 
the HLA-A*0201/NY-ESO-1157–165 complex we questioned whether anti-idiotypic antibodies also 
would activate re-directed T cells. Therefore, anti-idiotypic scFvs against the 3M4E5 CAR 
(recognizing HLA-A*0201/NY-ESO-1157–165) were selected from phage display library as 
described previously (Held, Matsuo et al. 2004). Two antibodies - A4 and H6 - which differ in the 
sequence of the variable domain were selected (data not shown). A4 and H6 scFv were cloned 
into bacterial expression vectors. After induction, both anti-idiotypic Fab molecules were 
expressed with an expected size of 25 kD (for each heavy and light chain) (figure 8A). Both, A4 
and H6 bound to anti-NY-ESO-1 antibody but not to the control antibodies (anti-VEGF or anti-
CD20 mAB) as analyzed by ELISA. Furthermore, A4 and H6 had similar binding properties to 
the anti-NY-ESO-1 antibody (figure 8B). 
 
Figure 4-8: Expression and purification of soluble anti-idiotypic Fab molecules (A4 and H6) binding to 
3M4E5 antibody recognizes the NY-ESO-1
157-165
 peptide in the context of HLA A*0201.A Two different 
purified anti-idiotypic Fab molecules on SDS PAGE gel (A4 and H6). B Binding of soluble purified anti-
idiotypic Fab molecules A4 (grey) and H6 (white) to immobilized anti HLA-A0201/NY-ESO-1157–165 
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(3M4E5) molecules was determined by ELISA. Anti-CD20 and anti-VEGF antibodies were used as 
control. ***P<0.0003 
4.5.2 Anti-idiotypic Fab A4 binds to cell surface expressed anti-NY-ESO-1 CAR (T1) 
To confirm that anti-idiotypic Fab A4 recognizes the anti-NY-ESO-1 CAR when expressed on 
the cell surface, anti-NY-ESO-1 CAR (T1) and anti-CEA CAR transfected 293T cells were used 
(75 to 90 % CAR expression; Figure 9A). As expected, anti-idiotypic Fab A4 as HLA-
A*0201/NY-ESO-1157–165 tetramer bound to anti-NY-ESO-1 CAR (T1) only (Figure 9B). A4 and 
A*0201/NY-ESO-1157–165 tetramer did not bind to control anti-CEA CAR. 
 
Figure 4-9: Surface binding of soluble purified Fabs to anti-NY-ESO-1 CAR (T1) transfected 293T cells. 
293T cells were transfected with anti-CEA CAR and anti-NY-ESO-1 CAR (T1). A Expression of both 
CARs was determined by staining with anti-human IgG antibody (dotted line).B Correct folding of anti-NY-
ESO-1 CAR was determined by staining with HLA-A*0201/NY-ESO-1157–165 tetramer-PE (dashed line). 
Fab (A4) bound to anti-NY-ESO-1 CAR (T1) (black line). As negative control, transfected 293T cells 
stained with irrelevant control Fab molecule (light grey). 
4.5.3 Affinity measurement of anti-idiotypic Fab A4 and competition with HLA-
A*0201/NY-ESO-1157–165tetramer 
Apparent affinity constant (KDapp) of the anti-idiotypic Fab A4 was measured on anti-NY-ESO-
1 CAR(T1) transfected 293T cells by analyzing the binding of serially diluted anti-idiotypic Fab 
A4 (Figure 10A). Half maximum fluorescence intensity was used to calculate the apparent 
affinity. Binding affinity of the anti-idiotypic Fab A4 to anti-NY-ESO-1 CAR(T1) was calculated 
as shown by KDapp values of 200 nM, which is comparable with data obtained from surface 
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Plasmon Resonance (SPR) on a CMS5 chip coated with anti-NY-ESO-1 Fab (data not shown). 
Next we analyzed the binding competition of anti-idiotypic Fab molecules with HLA-A*0201/NY-
ESO-1157–165 tetramer for anti-NY-ESO-1 CAR (T1), which was expressed on CD8
+ T cells. Anti-
NY-ESO-1 CAR re-directed CD8+ T cells were incubated with decreasing concentrations of anti-
idiotypic Fab A4 (1, 0.25, 0.03 μg/μl) and competed with known concentration of HLA-
A*0201/NY-ESO-1157–165 tetramer (0.002 μg/μl), 1 μg/μl of irrelevant Fab served as control for 
anti-idiotypic Fab. Inhibition of tetramer binding was determined by FACS analysis. HLA-
A*0201/NY-ESO-1157–165 tetramer binding was inhibited in a dose dependent manner as shown 
in figure 10B. These results indicate that anti-idiotypic Fab A4 competes with HLA-A*0201/NY-
ESO-1157–165 tetramer for anti-NY-ESO-1 CAR (T1) and completely blocks the binding of 
tetramer with anti-NY-ESO-1 CAR (T1) at high concentration of anti-idiotypic Fab A4. 
 
 
Figure 4-10: A For affinity studies, anti-idiotypic Fab molecules at various concentrations were incubated 
with NY-ESO-1 CAR transfected 293T cells. Detection was carried out with Penta-His, anti-mouse IgG 
(H+L) biotin, and streptavidin PE-antibody. For determination of apparent affinity of anti idiotypic Fab to 
anti-NY-ESO-1 Fab, half maximal binding concentration (KD) was calculated. B Competition between 
anti-NY-ESO-1 anti-idiotypic Fab molecules and HLA-A*0201/NY-ESO-1157–165 tetramer was analysed. 
Competition assay was performed with anti-NY-ESO-1 CAR (T1) re-directed CD8
+ 
T cells. Re-directed T 
cells were saturated with different concentrations of anti-idiotypic Fab A4 (wide dashed: 1 ug/ul, dashed: 
0.25 ug/ul, spotted: 0.03 ug/ul) and control Fab molecules (light grey: 1 ug/ul). After 15 minutes of 
incubation HLA-A*0201/NY-ESO-1157–165 tetramer (0.002 ug/ul, dark grey: tetramer only) was added to the 
cells. Competition was measured by flow cytometry. 
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4.5.4 Anti-idiotypic Fab A4 activates anti-NY-ESO-1 CAR (T1) re-directed CD8+T cells in 
vitro 
Purified human CD8+ T cells were transduced with anti-NY-ESO-1 CAR (T1) and anti-CEA 
CAR by retrovirus-mediated gene transfer. To address anti-idiotypic Fab dependent specific 
activation of anti-NY-ESO-1 CAR (T1) re-directed CD8+T cells IFNγ secretion was measured by 
ELISA. Cells were stimulated by plate-bound anti-idiotypic or control Fab. Anti-NY-ESO-1 
CAR(T1) grafted CD8+ T cells specifically secreted IFNγ in response to anti-idiotypic Fab A4, 
whereas no specific activation was observed in control Fab coated wells (figure 3A). Secretion 
of IFNγ was specific since only background levels of IFNγ were found in supernatants from anti-
CEA CAR re-directed CD8+ T cells (figure 11A). Next we compared the activation potential of 
the anti-idiotypic Fab A4 molecules and recombinant human HLA-A2 molecules pulsed with NY-
ESO-1157-165 peptide. Equimolar concentrations of both molecules were immobilized to cell 
culture plate for comparison. IFNγ secretion was measured by ELISA from the supernatants. 
Anti-NY-ESO-1 CAR (T1) re-directedCD8+ T cells secreted IFNγ through activation of solid 
phase bound anti-idiotypic Fab A4 and recombinant human HLA-A2 molecules in a dose 
dependent manner (figure 11B). Anti-idiotypic Fab A4 revealed significantly higher levels of 
IFNγ at 66 nM and 22 nM, when compared with human HLA-A2 molecules pulsed with 
NY-ESO-1157-165 peptide (Figure11 B). 
 
Figure 4-11: Anti-idiotypic Fab dependent activation of anti-NY-ESO-1CAR re-directed CD8+T cells. A 
Human CD8+T cells were retrovirally transduced with anti-NY-ESO-1CAR and anti-CEA CAR, equal 
number of CAR positive re-directed CD8+
 
T cells were cultured with plate-coated anti-idiotypic and control 
Fabs for 24h. As activation marker IFNγ was measured by ELISA in culture supernatant. B Equal 
numbers of recombinant HLA-A2 dimer molecule (pulsed with NY-ESO-1
157-165 
peptide) anti-idiotypic Fab 
molecules at different concentrations were coted on culture plates. Anti-NY-ESO-1 CAR re-directed T 
cells were added to the plate, after 24 hours culture supernatant was collected and secreted IFNγ was 
measured by ELISA.***P<0.0003 
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4.5.5 Anti-idiotypic Fab dependent expansion of anti-NY-ESO-1 CAR (T1) re-directed 
CD8+ T cells 
Since we demonstrated dose-dependent and antigen-specific activation of re-directed T cells by 
anti-idiotypic Fab as observed for HLA-A*0201/NY-ESO-1157–165 positive cells, we aimed to test 
anti-idiotypic Fab and target cells for the antigen-specific expansion of re-directed T cells. 
Receptor-triggered proliferation of re-directed CD8+ T cells was monitored induced by of anti-
idiotypic Fab A4 molecule or irradiated T2-1B (50Gy). We compared the antigen specific 
expansion of anti-NY-ESO-1 CAR (T1) re-directed CD8+ T cells with irradiated T2-1B (50Gy) 
cells or with anti-idiotypic Fab molecules. We monitored changes in CAR positive T cells and 
cell number over a period of 28 days. Increase in receptor positive cells was identified by 
surface staining with anti-human IgG antibody and the number was determined by counting 
viable cells on a weekly basis. Immobilized anti-idiotypic Fab A4 and T2-1B cells specifically 
increased the proliferation of anti-NY-ESO-1 CAR (T1) re-directed CD8+ T cells in contrast to 
control Fab (figure 12A and B). There was a significantly more rapid expansion of anti-NY-ESO-
1 CAR (T1) re-directed CD8+ T cells in response to anti-idiotypic Fab A4 Fab as compared to 
irradiated T2-1B cell stimulation. Considering the number of antigen specific T cells required for 
the adoptive T cell therapy, anti-idiotypic dependent expansion increases 150 fold of T cell 
number with in 28days compared with initial cell number and this cell number was double than 
cells derived by T2-1B cell dependent expansion (Figure 12B). 
 
Results 
Gopinadh Jakka  Page 46 
Figure 4-12: Antigen dependent expansion of anti-NY-ESO-1CAR re-directed CD8+ T cells. A At day 0, 
equal numbers of re-directed anti-NY-ESO-1 CD8+ cells were co-cultured with HLA-A*0201/NY-ESO-
1157–165 peptide expressing T2 cells (T2-1B) in a ratio of 4:1 or with anti-idiotypic Fab A4 (2 µg/ml) coated 
flasks in presence of rhIL-2 (50 IU/ml). Increase in receptor positivity and cell number was monitored for a 
period of 4 weeks. Increase in receptor positive T cells was analyzed by flow cytometry using PE-
conjugated anti-human IgG1 and FITC-conjugated anti-CD8 mAb. B Increase in number of receptor 
positive cells was counted on weekly basis. 
4.5.6 Functional analysis of CAR re-directed CD8+ T cells during in vitro expansion 
The functional capacity of the in vitro expanded anti-NY-ESO-1 CAR (T1) re-directed CD8+T 
cells in response to antigen-specific stimulation was analyzed. To address this question, we 
collected anti-NY-ESO-1 CAR (T1) re-directed CD8+ T cells at different time points of the 
expansion phase and co-incubated them with T2-1B (antigen specific) and T2-1C (control) for 
4h. Expanded anti-NY-ESO-1 CAR (T1) re-directed T cells were fully functional since they 
secreted cytokines (IFNγ, TNFα and IL-2) in an antigen-specific manner at day 28 (figure 13). 
Over time similar antigen-specific cytokine secretion trends were observed in both anti-idiotypic 
and T2-1B expanded re-directed T cells in response to antigen (figure 14 A and B).  
 
 
Figure 4-13.1: Comparison of the percentage of poly-functional antigen specific CAR re-directed CD8+ T 
cells after 28 day of expansion with T2-1B cells or anti-idiotypic Fab A4. Antigen-specific cytokine release 
was determined by intracellular staining. T2-1B and anti-idiotype Fab A4 expanded anti-NY-ESO-1 CAR 
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re-directed CD8+ T cells were incubated with T2-1B (antigen specific) and T2-1C (control) cells for 4 
hours. As positive control cells were stimulated withPMA/ionomycine. Percentage of IFNγ, TNFα and IL-2 
positive cells from T2-1B cell and anti-idiotypic Fab A4 expanded CAR positive CD8+ T cells. 
 
 
Figure 4-13.2: Activation of expanded anti-NY-ESO-1 CAR re-directed CD8+T cells. Percentage of poly-
functional antigen specific CAR re-directed CD8+ T cells were determined by intracellular cytokine 
staining for a period of 28 days. T2-1B and anti-idiotypic Fab A4 expanded anti-NY-ESO-1 CAR re-
directed CD8+ T cells were incubated with T2-1B (antigen specific) and T2-1C (control) cells for 4 hours. 
As positive control cells were stimulated with PMA/ionomycine. Percentage of IFNγ, TNFα and IL-2 
positive cells from T2-1B cell (A) and anti-idiotypic Fab A4 (B) expanded CAR positive CD8+
 
T cells at 
different time points of T-cell culture. (n=2, one representative experiment shown) 
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4.5.7 Expanded anti-NY-ESO-1 CAR (T1) expressing redirected CD8+ T cells lysed the 
antigen expressing target cells 
We further analyzed cytolytic potential of expanded anti-NY-ESO-1 CAR (T1) re-directed CD8 
positive T cells. Co-incubation of expanded anti-NY-ESO-1 CAR (T1) re-directed CD8+ T cells 
with T2-1B and T2-1C cells for 24 hours resulted in antigen-specifically lyses of T2-1B target 
cells regardless of the expansion protocol (figure 15 A and B), whereas no specific lysis was 
observed with T2-1C cells.  
 
 
Figure 4-14: Cytotoxicity of expanded re-directed T cells was assessed by measuring viability of target 
cells by a tetrazolium salt-based XTT assay after 24h. T2-1B (A) and anti-idiotypic Fab A4 expanded anti-
NY-ESO-1CAR re-directed CD8+T cells (B) were incubated with T2-1B (antigen specific, circles) and T2-
1C (control, squares) at different effector to target cell ratios. 
4.5.8 Phenotypic characterization of expanded re-directed CD8+ T cells 
For the phenotypic analysis of expanded anti-NY-ESO-1 CAR (T1) re-directed CD8+ T cells, we 
used a flow cytometric panel to distinguish different populations of central memory (CCR7+, 
CD62L+), effector memory (CCR7-, CD62L-) (Unsoeld and Pircher 2005) cells to compare the 
effect of anti-idiotypic Fab and T2-1B cells on phenotypinc change of anti-NY-ESO-1 CAR (T1) 
re-directed CD8+ T cells. The analysis was done with after day 28 in vitro expanded re-directed 
T cells. We have observed highly variable phenotypic difference between experiments. Anti-
idiotypic T cell expansion resulted either in high numbers or low numbers of central-memory re-
directed T cells depending on the donor.  
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Figure 4-15: CD62L and CCR7 expression on anti-idiotypic and T2-1B expanded anti-NY-ESO-1 CAR 
(T1) redirected CD8+ T cells. A CD62L and CCR7 staining onT2-1B expanded anti-NY-ESO-1 CAR (T1) 
positive re-directed CD8+ T cells. B CD62L and CCR7 staining on anti-idiotypic expanded anti-NY-ESO-1 
(T1) CAR positive re-directed CD8+ T cells 
4.5.9 Antitumor effect of expanded anti-NY-ESO-1 CAR (T1) re-directed CD8+ T cells in 
vivo 
To finally prove functionality of antigen-specially expanded re-directed T cells, re-directed CD8+ 
T cells were assessed in a Winn assay (Dent, Spencer et al. 1989). Winn assays can be used 
to demonstrate protection in xenograft models. It has been previously shown that freshly 
transduced anti-NY-ESO-1 CAR (T1) re-directed CD8+ T cells exhibit the anti-tumor effect in a 
protective mouse model (Schuberth, Jakka et al. 2012). In the herein performed Winn assay, 
NSG mice were subcutaneously injected with U266 cells (10x106). Co-injection was performed 
with either 10x106 anti-idiotypic or cell-based expanded anti-NY-ESO-1 CAR (T1) re-directed 
CD8+ T cells. Tumor growth was measured by the volume of the subcutaneous tumors and by 
measuring human IgE in the serum of mice. The Multiple myeloma U266 cells secret human 
IgE, which could be used as a surrogate parameter for cell growth. The control group injected 
with U266 cells alone started secreting human IgE after one week of injection whereas no IgE 
secretion was observed in anti-idiotypic expanded and T2-1B expanded CD8+ T cell groups. 
Increase in IgE levels were observed in control group mice up to day 35, whereas no IgE 
secretion was observed in anti-NY-ESO-1 CAR (T1) re-directed CD8+ T cells injected mice. The 
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growth of the subcutaneous tumor clearly indicated the anti-tumor activity of the expanded anti-
NY-ESO-1 CAR redirected CD8+ T cells. However, we have not observed differences between 
anti-idiotypic expanded and T2-1B expanded anti-NY-ESO-1 CAR (T1) re-directed CD8+ T cells 
regarding anti-tumor activity. These results demonstrated that growth of the Multiple myeloma 
cell line U266 was suppressed by expanded anti-NY-ESO-1 CAR (T1) re-directed CD8+ T cells 
in a Winn assay. 
 
Figure 4-16: Expanded anti-NY-ESO-1 CAR (T1) redirected CD8+ T cells mediate anti-tumor activity in 
Winn assay. Mice were subcutaneously injected 10 X 10
6 
U266 cells with 10 X 10
6 
of anti-idiotype, T2-1B 
expanded anti-NY-ESO-1 CAR redirected CD8+ T cells and PBS control. Tumor growth was monitored 
by measuring serum IgE levels (A) and tumor size (B) (n=2, one representative experiment shown). 
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5 Discussion 
Cancer immunotherapy aims to eliminate malignant cells by activating the immune system in an 
antigen specific manner; one way of eliminating malignant cells is by adoptive transfer of tumor 
specific T cells. Adoptive T cell transfer allows for the characterization and modification of T 
cells to target tumor cells and expand them in vitro in the absence of tumor suppressive 
mechanisms. Recent clinical trials with re-directed T cells showed promising results in patients 
with chronic lymphoid leukemia (Porter, Levine et al. 2011). Our study characterized HLA-
A2/NY-ESO-1157-165 re-directed CD8+ T cells in vitro and demonstrated the relevance of receptor 
affinities for adoptive T cell therapy. We have developed a method for the antigen specific 
expansion of clinical grade re-directed anti-NY-ESO-1 CAR positive T cells by using anti-
idiotypic Fab molecules. Our results indicate in vitro expanded anti-NY-ESO-1 CAR (chimeric 
antigen receptor) re-directed T cells are capable of antigen specific lysis of NY-ESO-1 157-165  
transfected T2 cells and inhibition of multiple myeloma tumor growth in xenograft model when 
analysed by a Winn assay system. 
First generation CARs had their antigen-binding domain connected to a transmembrane domain 
and CD3ζ intracellular signaling domain which showed anti-tumor efficacy in vitro by lysing 
tumor cells but in vivo efficacy was limited (Carpenito, Milone et al. 2009). Signaling through 
CD3ζ alone is not sufficient for the complete activation of re-directed T cells, resulting in a 
compromised cell proliferation, survival and antigen dependent IL-2 production in vivo. In 
physiological conditions, IL2 production in T cells is initiated by engagement of CD28 on 
activated antigen-specific T cells to its CD80/86 ligands on APCs (Fraser, Newton et al. 1992). 
Most of the malignant cells do not express CD28 ligands on their surface which leads to the loss 
of effectiveness of first generation CAR re-directed T cells in vivo. Intracellular signaling domain 
of CD28 is placed proximal to the CD3ζ in first generation CAR resulted in production of IL-2 
and provides antigen-specific signals 1 and 2 in CAR re-directed T cells called second 
generation CAR (Figure 2-6) (Savoldo, Ramos et al. 2011). HLA-A2/NY-ESO-1157-165 peptide 
complex recognizing anti-NY-ESO-1 scFv (wild type) and anti-NY-ESO-1 T1 scFv (affinity 
matured) were used to generate second generation CAR re-directed CD8+ T cells. In the 
present study, we show the expression of anti-NY-ESO-1 CAR constructs on the CD8+ T cell 
surface (Retroviral mediated gene transfer) and recognize NY-ESO-1157-165 peptide in context 
with HLA-A2 (figure 5-2).  
An effective antigen specific immune response generates different subsets of T cells including 
central memory, effector memory and effector cells (Sallusto, Geginat et al. 2004). We have 
reported that CAR re-directed CD8+ T cells consists of different T cell subpopulations 
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(Schuberth, Jakka et al. 2012). CAR re-directed CD8+ T cells show antigen specific activation 
and produce pro-inflammatory cytokines IFNγ, TNFα and IL-2 (Figure 5-4). It has been 
demonstrated that IFNγ, TNFα and IL-2 simultaneously producing T cells provide optimal 
effector function (Darrah, Patel et al. 2007). Our results from the cytokine analysis of either 
simultaneous (IFNγ, TNFα and IL-2) or individual cytokine secretion (IFNγ orTNFα or IL-2 ) by 
CAR re-directed CD8+ T cells indicate the existence of different phenotypic populations of 
CD8+ T cell subsets (Schuberth, Jakka et al. 2012).  
Tumor antigenic (mostly self-antigens) peptide presented MHC molecules interaction with 
specific TCRs tend to be of weaker affinity than TCR specific peptides originated from 
pathogens (Cole, Pumphrey et al. 2007). Selective replacement of one/two amino acids in the 
antigen binding region of TCRs resulted in increased affinity with antigen specificity (Li, Moysey 
et al. 2005). Previously, we found that affinity maturation by selective replacement of two amino 
acids in the light chain of our anti-HLA-A2/NY-ESO-1 157-165 TCR like Fab antibody molecule 
enhanced the affinity 20 fold (Stewart-Jones, Wadle et al. 2009). We have shown in the present 
study that both, wild type (anti-NY-ESO-1 CAR) and affinity matured (anti-NY-ESO-1 T1 CAR)  
chimeric antigen re-directed CD8+ T cells kept their specificity for the HLA-A2/NY-ESO-1157-165 
peptide. Moreover, higher affinity CAR re-directed CD8+ T cells significantly enhanced the 
antigen specific cytotoxic T cell activity. These results indicate that antigen specific affinity 
maturation of TCR like antibodies not only enhances the binding but also functionality of the 
scFv re-directed CD8+ T cells at lower effector (T cells) and higher target cell (T2-1B) ratios 
(figure 5-5). We also observed an enhanced antigen specific secretion of IFNγ and granzyme B 
molecules in in vitro culture supernatants with affinity matured scFv re-directed CD8+ T cells 
which was not observed with any other pMHC molecules.  
CD4 and CD8 expression on T helper cells and cytotoxic T lymphocytes (CTLs) is known to play 
a important role for the sensitivity and activity of T cells to their respective peptide MHC complex 
(Holler and Kranz 2003; Li, Dinner et al. 2004). Several studies have shown that antigen 
recognition by chimeric antigen receptors derived from monoclonal antibody is independent of 
MHC restriction. Furthermore, MHC class I restricted CD8+ and MHC class II restricted CD4+ T 
cells can be re-directed by chimeric antigen receptors (Hombach, Heuser et al. 2001). In this 
study, we demonstrate MHC restricted and co-receptor independent activation of chimeric 
antigen receptor recognizing HLA-A2/NY-ESO-1157-165 peptide re-directed T cells. Antigen 
specific activity of CAR re-directed CD4+ T cells is highly efficient and comparable with those of 
re-directed CD8+ T cells (Figure 5-6). Notably, increasing peptide density on target cell surface 
enhanced the T cell activation in both CD4+ and CD8+ re-directed T cells. It has been shown 
that CD4 and CD8 co-receptors play an important role in stabilizing the interaction between 
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TCR and peptide MHC complex under physiological conditions (Artyomov, Lis et al. 2010). 
Contrary to the findings, we observed that chimeric antigen receptors, derived from high affinity 
TCR like antibody targeting HLA-A2/NY-ESO-1157-165 peptide, re-direct the T cells in a co-
receptor independent manner. These findings are similar to that of high affinity MHC class I 
restricted TCRs targeting tumor antigens which also function in co-receptor independent 
manner (Schmid, Irving et al. 2010).  
It has been shown that the HLA-A2/NY-ESO-1157-165 peptide complex expression is enhanced 
after treatment with 5-aza-2-deoxycytidine (DAC) in different types of cancer cells (Guo, Hong 
et al. 2006). Several studies used DAC treatment to trigger the expression of p157-165 MHC 
complexes and, additionally, enhanceed the NY-ESO-1 specific CTL recognition (Coral, 
Sigalotti et al. 2002). The efficient anti-NY-ESO-1 T1 CAR re-directed CD8+ T cells recognition 
of DAC treated breast cancer cell line (MCF7) demonstrates that de novo synthesized NY-ESO-
1 is functional and it allows for specific T cell recognition of MCF7 cells that are otherwise 
completely resistant to anti-NY-ESO-1 T1 CAR re-directed CD8+ T cell mediated lysis. 
Moreover, activity of anti-NY-ESO-1 T1 CAR was enhanced in the Multiple myeloma cell line 
(U266) upon DAC treatment (figure 5-7). DAC treatment induced or enhanced the expression of 
NY-ESO-1 protein rather than increased expression of HLA class I molecules on the cell 
surface of tumor cells (Coral, Sigalotti et al. 1999). Thus, the anti-NY-ESO-1 T1 CAR re-directed 
CD8+T cell mediated lysis induced or enhanced by DAC treatment represents a direct 
consequence of NY-ESO-1 expression leading to sufficient amounts of immunogenic peptide 
loaded onto pre-existing HLA-A2 molecules in MCF7 cells which enabled efficient recognition of 
target cells by antigen specific T cells (Christinck, Luscher et al. 1991). 
Although cancer immunotherapy with tumor infiltrating lymphocytes (TILs) or re-directed T cells 
has shown significant activity in clinical settings, the expansion procedure requires simplification 
to allow for a broad range of applications (Ye, Loisiou et al. 2011) and, finally, to improve clinical 
outcome. It has been shown that sufficient numbers of T cells can be generated for the adoptive 
T cell therapy either by expanding TILs or re-directed T cells in vitro (Porter, Levine et al. 2006). 
In our study, we investigated the possibility of using anti-idiotypic Fab antibody molecules 
specific for the anti-NY-ESO-1 T1 CAR to boost the selective expansion of CAR re-directed 
CD8+ T cells. Anti-Idiotypic Fab antibody mediated expansion could be a valuable method to 
obtain sufficient numbers of tumor specific T cells for tumor targeting in the concept of adoptive 
T cell transfer. Our results were comparable with tumor specific T cells generated by other in 
vitro expansion protocols (Brimnes, Gang et al. 2012). In order to obtain sufficient numbers of 
tumor specific T cells for adoptive T cell therapy, tumor reactive CD8+ CTLs were either 
expanded with anti-human CD3/CD28 coated beads or expanded with APCs cells with weekly 
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stimulation (Li and Kurlander 2010). Expansion of T cells with anti-idiotypic Fab antibody 
molecules has several advantages compared to other expansion procedures. The most 
appealing advantage is these of purification and production of GMP grade anti-idiotypic Fab 
antibody molecules for the in vitro stimulation and expansion. Furthermore, anti-idiotypic Fab 
antibody molecules specifically activate CAR grafted CD8+T-cells from heterogeneous 
populations unlike polyclonal stimulation with anti CD3&CD28 antibodies (Teschner, Wenzel et 
al. 2011). Even though antigen specific T cells can be generated by loading peptides on artificial 
antigen presenting cells (aAPCs) or APCs, anti-idiotypic Fab antibody molecules provide cell-
free antigen specific expansion (Yuan, Gallardo et al. 2006). In this present study we observed 
that both anti-idiotypic Fab antibody molecules and antigen transfected T2 cells (T2-1B) can be 
used for the specific expansion of CAR grafted CD8+ T-cells. We also have demonstrated that 
anti-idiotypic Fab antibody molecules depended expansion is significantly more efficient than 
antigen transfected cell based expansion. Another advantage of using anti-idiotypic Fab 
antibody molecules over APCs is that the generation of antigen specific APCs requires a 
specialized laboratory and appropriate quality control (Papanicolaou, Latouche et al. 2003). We 
have demonstrated that anti-idiotypic Fab molecules bind to immobilized 3M4E5 IgG, to cell 
surface expressed scFv CARs on transfected 293T cells and freshly transduced human CD8+ T 
cells (figure 5-8), respectively. These anti-idiotypic Fab antibody molecules were comparable 
with HLA-A*0201/NY-ESO-1157–165 tetramer for the detection of surface expression of anti-NY-
ESO-1 CAR T1 and compete with the HLA-A2/NY-ESO-1157-165 tetramer for the CAR, which is 
expressed on transduced CD8 +T cells (figure 5-9&10).  
In addition to specific binding and competition with the antigen, we also compared the 
immobilized anti-idiotypic Fab antibody molecule with immobilized HLA-A*0201/NY-ESO-1157–165 
complex. Anti-idiotypic Fab antibody molecules can efficiently activate anti-NY-ESO-1 T1 CAR 
re-directed CD8+T-cells. Furthermore, we observed significantly higher activation potential of 
anti-idiotypic Fab antibody molecules with equal numbers of HLA-A*0201/NY-ESO-1157–165 
complexes (figure 5-11). Several studies have used CD3/CD28 beads or autologous APCs to 
successfully generate tumor specific T cells for adoptive T cell therapy (Rasmussen, Borelli et 
al. 2010). Peptide stimulation prior to the CD3/CD28 bead stimulation further increases the 
number of antigen specific T cells. We also observed similar results that anti-idiotypic Fab 
antibody dependent expansion specifically enhanced the number of anti-NY-ESO-1 T1 CAR re-
directed CD8+ T cells, more than that by antigen transfected T2-cells (figure 5-12). 
Adoptive transfer of tumor-specific memory cells T cells has been shown to be superior in tumor 
protection (Kim, Teh et al. 2009). Antigen specific T cells expanded in vitro with aAPCs 
comprise of central memory (CCR7+ CD62L+) and effector memory populations (CCR7- 
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CD62L-), adoptive transfer of these in vitro expanded T cells showed establishment of anti-
tumoral  immunological memory (Chapuis, Thompson et al. 2012). We observed similar results 
with anti-idiotypic Fab antibody dependent expansion of anti-NY-ESO-1 T1 CAR re-directed 
CD8+ T cells since the expanded population consisted of a central memory population (CCR7+ 
CD62L+) and effector memory population (CCR7- CD62L-). Moreover, we observed an 
increase of the central memory population with anti-idiotypic Fab antibody dependent expansion 
(figure 5-15). Repeated activation of T cells would result in activation induced cell death as 
observed in chronic viral infection and several tumor models (Saff, Spanjaard et al. 2004). We 
have observed a decrease in the antigen specific cytokine secretion over time, but antigen 
specific lysis of antigen expressing target cells was maintained (figure 5-13). T-cells expanded 
by anti-idiotypic Fab antibody show enhanced functional competence over other protocols when 
cytotoxicity and cytokine secretion are compared. Even though cells demonstrate cytotoxic 
potential after 28 days of expansion (figure 5-14), unfortunately, cytokine secretion decreases 
after 14 days of expansion. T-cells (14 days expanded) produce IFNγ, TNFα and IL-2 cytokines 
upon antigen specific stimulation which indicates the existence of memory T-cell population. We 
observed similar effect with anti-idiotypic and T2-1B cell dependent expansion. Moreover, anti-
idiotypic Fab antibody dependent expansion results in a 2 fold increase of numbers of 3M4E5 
CAR grafted T-cells than with T2-1B cell dependent expansion at day 14, which is 25 fold higher 
than that of starting population. 
Multiple myeloma (MM) is incurable neoplastic transformed plasma cells (Kyle and Rajkumar 
2008). It has been shown that conventional therapies may target plasma cells to reduce the 
tumor burden but they were ineffective in eradicating the disease (Matsui, Wang et al. 2008). 
Our previous study showed anti-tumor effect of anti-NY-ESO-1 T1 CAR in in vivo NSG mice 
model (Schuberth, Jakka et al. 2012). Functionality of the anti-idiotypic Fab antibody expanded 
T cells in vivo was demonstrated by co-injecting subcutaneously 10 X 106 U266 cells along with 
equal number of expanded re-directed T cells. It has been shown that growth of U266 cells in 
NSG mice can be monitored by measuring serum hIgE as a surrogate marker (Miyakawa, 
Ohnishi et al. 2004), and tumor volume was measured with caliper. Serum IgE levels were 
detected in mice with U266 PBS control after 7 days of injection whereas hIgE was not detected 
in mice injected with expanded CD8+ T cells even after 35 days of injection. Furthermore, we 
observed the tumor growth in U266 PBS control mice and they correlated with the increase of 
serum hIgE levels (5-16). Our results were comparable with other T cell expansion protocols.  
Finally, our data demonstrate that anti-NY-ESO-1 CAR re-directed T cells have higher affinity, 
exhibit strong anti-tumor activity and the activity is enhanced by the increase in the endogenous 
NY-ESO-1 peptide by de-methylating agent. Re-directed CD8+ T cells are composed of 
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different T cell populations like central memory and effector memory cells and showed antigen 
specific functionality in vitro. Required numbers of tumor specific CAR grafted CD8+T-cells can 
be generated by using anti-idiotypic Fab antibody molecules for adoptive T cell transfer and 
yields higher number of tumor specific T cells compared to T cells derived by T2-1B cell 
dependent expansion. After 28 days of expansion, we show the functionality of these expanded 
T-cells is maintained as good as tumor cell expanded T cells. 
Taken together these findings indicate usage of anti-idotypic Fab antibody dependent cell free 
system for adoptive T-cell transfer studies as a novel method for the expansion of clinical grade 
TCR like antibody CAR grafted CD8+T-cells.  
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